Document:

<PAGE>

                                                                   Exhibit 10.29

          RESOLVER-TM- SYSTEM EARLY ACCESS PROGRAM AND LICENSE AGREEMENT

          This Agreement (hereinafter "Agreement"), effective as of September
30, 1999, (hereinafter "Effective Date") is made by and between DuPont
Pharmaceuticals Company ("DuPont"), a Delaware general partnership, with offices
at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805 and Rosetta
Inpharmatics, Inc. ("Rosetta"), a Delaware corporation, with principal offices
at 12040 - 115th Avenue Northeast, Kirkland, Washington 98034.

                                    RECITALS

          1.       DuPont is a worldwide business that focuses on research,
                   development, and delivery of pharmaceuticals to treat unmet
                   medical needs in the fight against AIDS, cardiovascular
                   disease, central nervous system disorders, cancer and
                   arthritis-related disorders.

          2.       Rosetta is developing a new gene expression analysis platform
                   known as the Resolver-TM- System that can be used to
                   interrogate and analyze complex pharmacological effects.

          3.       DuPont desires early access to pre-commercial release
                   versions of the Resolver-TM- System for internal use.

          4.       Rosetta desires feedback on the features and capabilities of
                   the Resolver-TM- System to assist it in the continued
                   development of this system.

                              TERMS AND CONDITIONS

          NOW, THEREFORE, in consideration of the mutual covenants expressed in
this Agreement, DuPont and Rosetta agree as follows:

                             ARTICLE 1-- DEFINITIONS

          1.1 "AGREEMENT" means this agreement and all the attachments hereto.

          1.2 "CONFIDENTIAL INFORMATION" means any Information received by one
party (the Receiving Party) from another party (the Disclosing Party) that is
treated by the Disclosing Party as confidential, provided that such information,
(i) if in written form, is marked "Confidential" or "Proprietary," or (ii) if in
other than written form and although not marked "Confidential" or "Proprietary"
and not otherwise identified by the Disclosing Party as confidential, is of such
a nature that a reasonable person would treat it as confidential or proprietary,
unless such information:

          (a) was known to the Receiving Party prior to receipt from the
Disclosing Party, as shown by appropriate evidence;

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

<PAGE>

          (b) was lawfully available to the trade or to the public prior to
receipt from the Disclosing Party;

          (c) becomes lawfully available to the trade or to the public after
receipt from the Disclosing Party through no act on the part of the Receiving
Party;

          (d) corresponds in substance to any information received in good faith
by the Receiving Party from any third party without breach of any obligation of
confidentiality; or

          (e) is communicated to any third party by the Disclosing Party without
restriction as to confidentiality or on the basis of a restriction that has
lapsed.

          1.3 "DELIVERABLE" means a specific tangible thing or task identified
in the Agreement as something that must be delivered by one Party to the other,
usually by a date specified in the Agreement, and which may trigger an
obligation upon the part of, or a response by, the recipient.

          1.4 "DISCLOSING PARTY" when used in reference to Confidential
Information means the Party that discloses Confidential Information to the
Receiving Party by furnishing documents or other media containing Confidential
Information, by orally disclosing Confidential Information, or by permitting
visual inspection of something considered confidential.

          1.5 "EARLY ACCESS PROGRAM" OR "PROGRAM" means the arrangement between
the Parties pursuant to this Agreement whereby DuPont has access to the
Resolver-TM- System prior to its commercial release for internal use only, and
provides feedback to Rosetta regarding the Resolver-TM- System together with the
Resolver-TM- Software so that Rosetta can continue its development efforts in
respect thereof.

          1.6 "FEATURE-COMPLETE RELEASE" means a version of the Resolver-TM-
Software that contains all of the features and capabilities that Rosetta will
provide at the beginning of Stage 3. For a description of these features, see
Appendix A, Stage 3. The Feature-Complete Release delivered to DuPont under this
Agreement will be a beta version, i.e., a version that is still undergoing
testing prior to commercial release.

          1.7 "INFORMATION" means business and technical information learned or
received by a Party from or about the other Party prior to and during the term
of this Agreement, and includes, by way of example, the terms of this Agreement,
information relating to products or manufacturing capabilities of any Party,
customer lists, computer programs or other software, user documentation for
software, business methods and plans for future developments, know-how, trade
secrets, inventions, other intellectual property, innovations, improvements,
discoveries, formulae, techniques, processes, approaches, concepts, data,
reports, opinions, blueprints, diagrams, schematics, charts, machines,
specifications, drawings, plans, articles of manufacture, samples, parts lists,
log books, and research reports, as well as requests for quotes, proposals, and
purchase orders.

          1.8 "INITIAL FEATURE RELEASE" means a version of the Resolver-TM-
Software that does

                                      -2-
<PAGE>

not contain all of the features and capabilities of the Feature-Complete
Release. For a description of features that Rosetta will provide with the
Initial Feature Release, see Appendix A, Stage 1.

          1.9 "INTELLECTUAL PROPERTY RIGHTS" shall mean any patents, patent
applications, trademarks, copyrights, know-how, moral rights, and similar rights
of any type under the laws of any governmental authority, domestic or foreign,
including all applications and registrations relating to any of the foregoing.

          1.10 "PARTY" AND "PARTIES" refer to and mean DuPont or Rosetta, as the
context requires.

          1.11 "RECEIVING PARTY" when used in reference to Confidential
Information means the Party that receives Confidential Information from the
Disclosing Party in documents or other media containing Confidential
Information, or orally during a presentation or discussion disclosing
Confidential Information, or through visual inspection of something considered
confidential.

          1.12 "RESOLVER-TM- SOFTWARE" OR "SOFTWARE" means the gene expression
analysis software and database, including its schema, licensed hereunder that is
being developed by Rosetta as part of the Resolver-TM- System and any derivative
works, or any changes, modifications, corrections, improvements, or extensions
to the Software. The Resolver-TM- Software consists of Reso1ver-TM- Server
Software" and one or more copies of Resolver-TM- Client Software.

          1.13 "RESOLVER-TM- CLIENT SOFTWARE" means one or more copies of a
Resolver-TM- Software client application that resides on desktop computers
operated by a user at DuPont.

          1.14 "RESOLVER-TM- SERVER SOFTWARE" means that part of the
Resolver-TM- Software that resides on the Server.

          1.15 "RESOLVER-TM- SYSTEM" as used herein means a system consisting of
the hardware and software components described in Section 4.1.

          1.16 "SECOND FEATURE RELEASE" means a version of the Resolver-TM-
Software that has features in addition to the features available in the Initial
Feature Release, but fewer features than the Feature-Complete Release. For a
description of features that Rosetta will provide with the Second Feature
Release, see Appendix A, Stage 2.
          1.17 "SERVER" shall have the meaning ascribed thereto in Section
4.1.1.

          1.18 "TERM" shall have the meaning ascribed thereto in Section 7.1.

                  ARTICLE 2 -- OVERVIEW OF EARLY ACCESS PROGRAM

         2.1 OVERVIEW OF THE PROGRAM. Rosetta hereby undertakes to provide
DuPont with early access to the Resolver-TM- System and DuPont hereby agrees to
cooperate with Rosetta on development and improvement of the Resolver-TM-
System. The Program will consist of three (3)

                                      -3-
<PAGE>

phases or stages that correspond to delivery of different versions of
Resolver-TM- Software to DuPont. For Stages 1 and 2 of the Program, Rosetta
will provide DuPont with access to the Initial Feature Release and Second
Feature Release, respectively, of the Resolver-TM- Software that will reside
on a Server owned by DuPont and located at Rosetta's premises. DuPont will
access the Resolver-TM- System over a secure connection such as a virtual
private network or a private virtual circuit. Rosetta will deliver, when
available, a beta version of the Feature-Complete Release for Stage 3, which
will likewise initially reside on the Server located at Rosetta's premises and
then be transferred to DuPont's premises. The parties expect that DuPont's
early use of the Resolver-TM- System, together with DuPont's feedback regarding
the performance thereof, will assist Rosetta in the development program for the
Resolver-TM- System and the Resolver-TM- Software, as well as benefit DuPont by
providing early access to a gene expression data analysis solution at a price
less than the anticipated price that will be charged to customers when the
Feature-Complete Release version of the Resolver-TM- System is available. This
Agreement sets out the duties and obligations of each Party for the Early
Access Program.

          2.2 UNFINISHED SOFTWARE. DuPont and Rosetta acknowledge and agree that
the Initial Feature Release, Second Feature Release, and Feature-Complete
Release versions of the Resolver Software will likely contain bugs, defects, and
errors, and that the Software is not expected by either DuPont or Rosetta to
function error-free upon installation. DuPont and Rosetta further acknowledge
and agree that the Resolver-TM- Software is being provided to DuPont on an early
access basis to provide Rosetta with feedback to evaluate and improve its
Resolver-TM- System.

          2.3 EXPECTATIONS OF THE PARTIES. Each of the Parties shall use its
commercial best efforts to perform the tasks that are assigned to it as set
forth in this Agreement.

                    ARTICLE 3 -- LICENSE SCOPE AND MANAGEMENT
                           OF THE EARLY ACCESS PROGRAM

          3.1 LIMITED SOFTWARE LICENSE.

          3.1.1 GRANT OF LICENSE.
Subject to full and timely payment of all amounts due Rosetta under Article 6
and subject to the other terms and conditions of this Agreement, Rosetta
hereby grants DuPont a nonexclusive, nontransferable, revocable license to
use the Software (in object code form only, and without any right to
sublicense or make derivative works or any changes, modifications,
corrections, improvements, or extensions of the Software) for internal use
only in the United States pursuant to the virtual private network established
hereunder to connect DuPont to the Resolver-TM- System located at Rosetta's
premises during Stages 1 and 2, and thereafter during the Term of this
Agreement at DuPont's site located at Experimental Station, Wilmington,
Delaware. The License includes only rights under presently existing patents
and copyrights and only to the extent necessary to use the Resolver-TM-
Software as delivered and only when using the Resolver-TM- System as provided
by Rosetta. Upon expiration or termination of this Agreement all rights and
licenses granted to DuPont pursuant to this Agreement with respect to the
Resolver-TM- Software shall revert to Rosetta and DuPont shall retain no
rights therein.

         3.1.2 RESTRICTIONS. DuPont agrees that it and
its employees, consultants, and

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -4-
<PAGE>

representatives will not directly or indirectly (i) subject to Section 12.5,
sell, lease, assign, sublicense, or otherwise transfer, (ii) duplicate,
reproduce, or copy, (iii) disclose, divulge, or otherwise make available to any
third party, (iv) use except as authorized by this Agreement, or (v) decompile,
disassemble, reverse engineer, or otherwise analyze for reverse engineering
purposes, the Software or any portion thereof, including all trade secrets and
Confidential Information therein. DuPont is granted no title or ownership rights
to the Software, and all such rights shall remain with Rosetta. DuPont shall use
its best efforts to prevent inadvertent disclosure of the Software or any
portion thereof, including all trade secrets and Confidential Information
therein. DuPont shall not permit any third party, nor any employee, consultant,
representative, or agent thereof, that develops, markets, or licenses computer
programs with functionality similar to the functionality of the Software to have
access to the Software or to any trade secrets or Confidential Information
therein. The Resolver-TM- Client Software may be installed on up to [***]
DuPont desktop computers concurrently.

          3.1.3 TERM OF LICENSE. The license to the Software granted by this
Agreement shall expire concurrently with the expiration or termination of this
Agreement as set forth in Article 7.

          3.1.4 DELETION OF SOFTWARE; RETURN OF DOCUMENTATION AND MATERIALS.
As soon as practicable following any termination or expiration of this
Agreement (and in no event more than five (5) business days thereafter),
DuPont shall (i) permit Rosetta to permanently delete (a) the Resolver-TM-
Software from the Server located at Rosetta's premises or such other location
at which a Server on which the Software is loaded is then situated and (b)
the Resolver-TM- Client Software installed on desktop computers at DuPont's
premises, (ii) return to Rosetta all written Information provided by, or on
behalf of, Rosetta to DuPont including, but not limited to, Software
documentation, and (iii) permanently delete or permit Rosetta to permanently
delete any other copies of the Software from all computer systems under
DuPont's control. Upon request by Rosetta, DuPont will certify in writing to
DuPont's compliance with this Section 3.1.4.

          3.2 DESIGNATION OF PROGRAM CONTACT. Each Party shall designate an
appropriate person, and if necessary a replacement, to serve as its contact for
the Program ("Program Contact"). Rosetta's Program Contact initially will be
Doug Bassett, Ph.D., and DuPont's Program Contact initially will be Ken
Abremski, Ph.D.

          3.3 RESPONSIBILITIES OF PROGRAM CONTACT. The Program Contacts shall
represent their respective Parties on all business issues pertaining to the
subject matter of this Agreement. The Program Contact shall be the person whom
the other Party contacts initially on all business issues. The Program Contacts
shall be responsible for developing and maintaining communications between the
Parties, determining the status of all activities required or contemplated by
this Agreement, monitoring the other Party's compliance with the provisions of
this Agreement, and generally promoting a healthy relationship between the
Parties. The Program Contacts shall confer as needed to ensure that technical
questions and administrative issues are satisfactorily addressed and resolved.

         3.4 TESTING AND FEEDBACK ON RESOLVER-TM- SYSTEM. On a periodic basis
during Stages 1, 2, and 3 of this Agreement as may be agreed from time to time
between the Program

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -5-
<PAGE>

Contacts, b t in no case less than every [***], the Program Contacts or
their designees shall meet or confer to discuss the experience and feedback of
DuPont users regarding the Resolver-TM- System. One week prior to each feedback
session, DuPont's Program Contact will provide Rosetta's Program Contact with a
written summary of the feedback that will be discussed at the meeting.

          3.5 ACCESS TO RESOLVER-TM- SYSTEM. DuPont shall allow Rosetta to have
access to the Resolver-TM- System for the purpose of using, testing, modifying,
and correcting the Software, PROVIDED, HOWEVER, that such access shall not
materially disrupt DuPont's use of the Resolver-TM- System.

          3.6 RIGHT OF ROSETTA TO DUPONT'S FEEDBACK. DuPont agrees that Rosetta
shall have, subject to Article 8, the unlimited right to use without
compensation to DuPont, in any manner and for any purpose, any and all
information about the Resolver-TM- System gained by DuPont as a result of
DuPont's use and evaluation of the Resolver-TM- System. Such information shall
include, but not be limited to, any derivative works, changes, compilations,
modifications, corrections, improvements, and extensions to the Resolver-TM-
System suggested or identified by DuPont. Rosetta shall have the right to use,
at its sole discretion, all such information including, but not limited to, use
by incorporation of such information into computer programs and documentation
for assignment, license, or other transfer to third parties, without any duty
to account to DuPont, and DuPont hereby agrees that it will not assert any
claims against Rosetta or its assignees or sublicenses with respect to
Rosetta's or its assignees' or sublicenses' practice, use, licensing,
manufacturing, marketing, sale or distribution of the Resolver-TM- System or
Software or any product similar to either thereof that incorporates or utilizes
any of such information.

          3.7 NO OBLIGATION TO SUPPORT SOFTWARE. Except as expressly set forth
in Article 5, Rosetta shall have no obligation to correct any bugs, defects, or
errors in the Resolver-TM- System or to otherwise support or maintain the
Software.

          3.8 OWNERSHIP OF RESOLVER-TM- SOFTWARE. DuPont agrees that Rosetta
owns all rights, title, and interest including, but not limited to, Intellectual
Property Rights, in the Resolver-TM- Software and any derivative works, changes,
compilations, modifications, corrections, improvements, or extensions to the
Software and Rosetta has the right to file for or otherwise secure and protect
such rights. If DuPont is ever held or deemed to be the owner of any
Intellectual Property Rights or other rights in the Software or any derivative
works, changes, compilations, modifications, corrections, improvements, or
extensions of the Software, then DuPont hereby irrevocably assigns to Rosetta
all such rights, title, and interest and agrees to execute and deliver all
documents and take such other actions as shall be necessary or advisable to
create and secure all such rights, title, and interest in Rosetta at Rosetta's
sole expense.

          3.9 ROSETTA GENE EXPRESSION DATA PROVIDED WITH RESOLVER-TM- SYSTEM.
Rosetta provides gene expression data with the Reso1ver-TM- System for use in
tutorial sessions. DuPont acknowledges and agrees that Rosetta's gene expression
data are being provided free of charge and without compensation. DuPont agrees
that Rosetta owns all rights, title, and interest including, but not limited to,
Intellectual Property Rights in the gene expression data. DuPont acknowledges
and agrees that such gene expression data are to be used only for internal
tutorial

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -6-
<PAGE>

purposes. DuPont agrees that it and its employees, consultants, and
representatives will not, directly or indirectly, (i) subject to Section 12.5,
lend, sell, lease, assign, or otherwise transfer, (ii) duplicate, reproduce, or
copy , (iii) show, disclose, divulge, discuss, or otherwise make available to
any third party, (iv) export or import to another database or software tool, (v)
use except as authorized by this Agreement, or (vi) analyze for research
purposes, Rosetta's gene expression data or any portion thereof, including all
trade secrets and Confidential Information therein. DuPont is granted no title
or ownership rights to the gene expression data, and all such rights shall
remain with Rosetta. Any inventions, discoveries, or Intellectual Property
Rights arising or related to use of these gene expression data shall belong to
Rosetta. If DuPont is ever held or deemed to be the owner of any Intellectual
Property Rights or other rights in any inventions or discoveries based upon
Rosetta's gene expression data, then DuPont hereby irrevocably assigns to
Rosetta all such rights, title, and interest and agrees to execute and deliver
all documents and take such other actions as shall be necessary to carry out and
effectuate the intent of this Agreement. Rosetta hereby grants DuPont a first
right to negotiate an exclusive license for such Intellectual Property Rights
upon terms and conditions to be negotiated between the Parties.

          3.10 DESUPPORT NOTIFICATION. Rosetta will notify DuPont's Program
Contact at least thirty (30) days before support for an old version of the
Software is to be terminated.

          3.11 DUPONT'S Oracle Site License. DuPont certifies that it has an
Oracle Enterprise site license, and that this site license will cover Oracle
licensing requirements of the Resolver-TM- System for Stages 1, 2 and 3 of
this Agreement.

          3.12 DUPONT'S EXPERIMENTAL DATA. In its use of the Resolver-TM-
System, DuPont will be loading experimental data into the Resolver-TM- Software
("DuPont Data"). Rosetta acknowledges and agrees that DuPont Data is
Confidential Information as defined in Section 1.2. Rosetta agrees that DuPont
owns all rights, title, and interest including, but not limited to, Intellectual
Property Rights in the DuPont Data. Rosetta agrees that it and its employees,
consultants, and representatives will not, directly or indirectly, (i) lend,
sell, lease, assign, or otherwise transfer, (ii) duplicate, reproduce, or copy,
(iii) show, disclose, divulge, discuss, or otherwise make available to any third
party, (iv) export or import to another database or software tool, or (v)
analyze for research purposes DuPont Data or any portion thereof, including all
trade secrets and Confidential Information therein. Rosetta is granted no title
or ownership rights to the DuPont Data, and all such rights shall remain with
DuPont.

          3.13 NOTICES. Formal notices required or permitted hereunder shall be
given in writing. Written notices may be delivered personally, sent by first
class mail to the address indicated below, or transmitted electronically by
facsimile transmission ("faxed") to the fax telephone number indicated herein.
All notices or other communications required or permitted hereunder shall be
deemed to have been given (i) if sent by facsimile with confirmed transmission
(accompanied by same day deposit of the original in the U.S. Mail, first-class
postage prepaid, and properly addressed), on the next business day following
facsimile transmission, (ii) if by personal delivery to the proper address, on
the date of such delivery, (iii) if by overnight courier service to the proper
address, on the second business, day following deposit if delivered within the
same country, or on the third business day following deposit if

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -7-
<PAGE>

delivered to another country or (iv) if mailed, postage prepaid first class
certified or registered mail, return receipt requested, on the fourth business
day after mailing if mailed within the same country as that of the addressee and
on the seventh business day after mailing if mailed to addressee in another
country, to the address designated below or to such other address as a Party may
designate to the other in writing:

DuPont Pharmaceutical Company                     Rosetta Inpharmatics, Inc.
974 Centre Road                                   12040 - 115th Avenue NE
Wilmington, Delaware 19805                        Kirkland, WA 98304
Attn: Ken Abremski, Ph.D.                         Attn: Chief Operating Officer
Fax: (302) 695-9420                               Fax: (425) 820-5757

with a copy to:                                   with a copy to:
DuPont Pharmaceutical Company                     Rosetta Inpharmatics, Inc.
974 Centre Road                                   12040- 115th Avenue NE
Wilmington, Delaware 19805                        Kirkland, WA 98034
Attn: Legal Division                              Attn: Legal Dept.

          ARTICLE 4 -- DESCRIPTION OF RESOLVER-TM- SYSTEM AND CONNECTION

          4.1 RESOLVER-TM- SYSTEM. The Resolver-TM- System consists of the
hardware and software components described in this Section 4.1.

          4.1.1 SERVER.

          4.1.1.1 HARDWARE. The hardware upon which the Resolver-TM- Server
Software will be initially loaded is a Sun EnterpriseTM "35xx" server that will
include two (2) central processing units "(CPU"), four (4) gigabytes of random
access memory, one A5200 drive array that has two hundred (200) gigabytes of
capacity, and an Ll000 tape backup device that has one (1) terabyte of capacity.
Configuration of the Server and any modifications to the Server during Stages 1
and 2 must be conducted or authorized by Rosetta for the Resolver-TM- System to
qualify for the maintenance and support set forth in Article 5. Any
modifications to the Server hardware or Server software during Stages 1, 2, or 3
of this Agreement that are not approved in writing by Rosetta will cancel
Rosetta's obligations for providing maintenance and support as set forth in
Article 5.

         4.1.1.2 OWNERSHIP OF HARDWARE. Rosetta agrees to sell and DuPont agrees
to purchase the [***]. Rosetta and DuPont hereby confirm their intent that the
Server shall be deemed property of DuPont even though it may become attached
or affixed to realty on the premises of Rosetta, and title thereto shall
remain in DuPont or its assigns exclusively. DuPont may require plates or
markings to be affixed to the Server indicating DuPont's interest. While the
Server is on Rosetta's property and in its possession, Rosetta shall be
responsible therefor, and shall protect DuPont against any loss of, or damage
to such property through insurance coverage with limits and terms and
conditions satisfactory to DuPont. [***]

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -8-
<PAGE>

          4.1.1.3 SERVER SOFTWARE. The Server will be loaded with the
following non-Rosetta commercial software applications as well as other
applications deemed necessary by Rosetta for the Resolver-TM- System: (1)
[***], (2) [***], (3) [***], (4) [***], and (5) [***].

          4.1.2 RESOLVER-TM- SOFTWARE. The Server will be loaded with the
applicable version of Rosetta's Resolver-TM- Server Software and software for
installation of the Resolver -TM- Client Software on compliant DuPont desktop
computers.

          4.2 LOCATION OF RESOLVER-TM- SYSTEM. During Stages 1 and 2 as
described in Article 5, the Resolver-TM- System will be on the premises of
Rosetta to assist in the maintenance of the system. During Stage 3, the parties
expect that the Resolver-TM- System will be relocated to a location specified
by DuPont. Rosetta and DuPont may mutually agree to move the Server to DuPont's
premises prior to Stage 3.

          4.3 SERVER HARDWARE UPGRADES. Rosetta recognizes that after the
initiation of Stage 1 of the Program, DuPont may want to upgrade the Server by,
for example, installing additional CPUs or additional memory to increase the
performance of the Resolver-TM- System. DuPont shall notify Rosetta of the
desire to perform such upgrades for a determination by Rosetta of whether any
modifications or corrections must be made to the Resolver-TM- Software. DuPont
shall be free to purchase hardware upgrade components from whatever source it
desires. If DuPont desires to perform a Server upgrade during Stages 1 and 2
and desires to have Rosetta perform the upgrade, this will be classified as
"service" as set forth in Section 5.6. Shipping and installation of Server
components will be paid by DuPont.

          4.4 CONNECTION TO THE RESOLVER-TM- SYSTEM. For Stages 1 and 2, and
during Stage 3 for so long as the Server shall remain located on Rosetta's
premises, DuPont will be connected to the Resolver-TM- System using a secure
connection such as a virtual private network ("VPN") with the specifications
set forth in Appendix B or equivalent thereof.

          4.5 MATERIALS AND EQUIPMENT. Whenever materials, equipment, or third
party commercial software applications are specified or described in this
Agreement by using the name of a proprietary item or the name of a particular
supplier, the naming of the item is intended to establish the type, function and
quality required, and substitute materials or equipment may nonetheless be used;
provided that such materials or equipment are materially equivalent or equal to
that named. If Rosetta wishes to furnish or use a substitute item of material
or equipment, Rosetta must first certify that the proposed substitute will
perform at least as well the functions described in this Agreement and will be
of materially equal substance to that specified and be suited for the same use
as that specified. DuPont may require Rosetta to furnish, at Rosetta's expense,
reasonable amounts of additional data about the proposed substitute as required
to evaluate the substitution. DuPont will be allowed a reasonable time, not to
exceed [***], within which to evaluate each proposed substitute.

                  ARTICLE 5- DELIVERABLES AND RESPONSIBILITIES

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -9-
<PAGE>

          5.1 STAGE 1. Stage 1 shall begin with delivery of the Resolver-TM-
System with an Initial Feature Release of Resolver-TM- Software and shall end
upon the beginning of Stage 2. Rosetta anticipates delivery of the Resolver-TM-
System with an Initial Feature Release of the Resolver-TM- Software within
[***] of the Effective Date.

          5.1.1 STAGE 1 DELIVERABLES BY ROSETTA. For Stage 1, Rosetta will
provide the following:

          5.1.1.1 Delivery of the Resolver-TM- System described in Article 4
with an Initial Feature Release of the Resolver-TM- Software;

          5.1.1.2 User documentation for the Resolver-TM- System;

          5.1.1.3 [***] of training at Rosetta regarding use of the Initial
Feature Release for the Resolver-TM- Software for up to [***] individuals
from DuPont with transportation and lodging paid for by DuPont;

          5.1.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
during Stage 1;

          5.1.1.5 Maintenance of the Resolver-TM- Server while it is located on
Rosetta's premises during Stage 1; and

          5.1.1.6 Installation at DuPont's location by Rosetta with the
cooperation of DuPont's staff of the VPN hardware and software necessary to
satisfy the minimum specifications set forth in Appendix B.

          5.1.2 STAGE 1 RESPONSIBILITIES OF DUPONT. For Stage 1, DuPont will
provide the following:

          5.1.2.1 Desktop computers located at a site to be determined by DuPont
for use with the Resolver-TM- System having the minimum specifications set forth
in Appendix C;

          5.1.2.2 Installation of Resolver-TM- Client Software onto the desktop
computers identified in Section 5.1.2.1;

          5.1.2.3 An internal computer network with l00BaseT network bandwidth
to each user's desktop CPU; and

          5.1.2.4 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3.

          5.2 STAGE 2. Stage 2 shall begin with installation of the Second
Feature Release onto the Server by Rosetta and shall end upon the beginning of
Stage 3. Rosetta anticipates delivery of the Second Feature Release within three
(3) months after the Effective Date. Rosetta will discontinue support for the
Initial Feature Release delivered in Stage 1 upon the initiation of

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -10-
<PAGE>

Stage 2.

          5.2.1 STAGE 2 DELIVERABLES BY ROSETTA. For Stage 2, Rosetta will
provide the following:

          5.2.1.1 The Second Feature Release with the additional analytical
features set forth in Appendix A;

          5.2.1.2 Additional user documentation for the Resolver-TM- System;

          5.2.1.3 [***] of training at Rosetta regarding use of the Second
Feature Release for the Resolver-TM- Software for up to [***] individuals from
DuPont with transportation and lodging paid for by DuPont;

          5.2.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
during Stage 2; and

          5.2.1.5 Maintenance of the Resolver-TM- Server while it is located on
Rosetta's premises during Stage 2.

          5.2.2 Stage 2 Responsibilities of DuPont. For Stage 2, DuPont will
provide the following:

          5.2.2.1 Installation of an upgrade for the Resolver-TM- Client
Software for the Second Feature Release onto the desktop computers identified
in Section 5.1.2.1; and

          5.2.2.2 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3.

          5.3 STAGE 3. Stage 3 shall begin with installation of the
Feature-Complete Release of Resolver-TM- Software onto the Server. Rosetta
anticipates availability of a beta version of the Feature-Complete Release of
the R Resolver-TM- Software by January 2000. The Server with the Feature-
Complete Release software will then be delivered and installed at a site
specified by DuPont. Stage 3 will end one (1) year after initiation of
Stage 1. Rosetta will discontinue support for the Second Feature Release
delivered in Stage 2 upon the initiation of Stage 3.

          5.3.1 STAGE 3 DELIVERABLES BY ROSETTA. For Stage 3, Rosetta will
provide the following:

          5.3.1.1 Delivery and installation to a site specified by DuPont of the
Resolver-TM- System described in Article 4 and previously located at Rosetta's
premises with a beta version of the Feature-Complete Release;

          5.3.1.2 Additional user documentation for the Resolver-TM- System;

          5.3.1.3 [***] day of on-site training at DuPont regarding use of the
features provided by the Feature-Complete Release for up to [***] individuals
from DuPont

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -11-
<PAGE>

with the transportation and lodging for the Rosetta trainer paid for by Rosetta;

          5.3.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
for one (1) year from initiation of Stage 3; and

          5.3.1.5 Upgrade protection for one (1) year from initiation of Stage
3. Upgrade protection shall mean that any new versions, service packs, or
patches of the Resolver-TM- Software will be made available to DuPont without
charge when available. Installation of a new version, service pack, or patch by
Rosetta under this upgrade protection provision shall be performed by DuPont or,
if DuPont wishes Rosetta to perform this service, it will be charged against the
service credit described in Section 5.6.

          5.3.2 STAGE 3 RESPONSIBILITIES OF DUPONT. For Stage 3, DuPont will
provide the following:

          5.3.2.1 Installation of an upgrade for the Resolver-TM- Client
Software for the Feature-Complete Release onto the desktop computers identified
in Section 5.1.2.1;

          5.3.2.2 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3;

          5.3.2.3 An appropriate physical location for the Server at DuPont; and

          5.3.2.4 Network access by Rosetta to the Server located on DuPont's
premises to permit remote access support by Rosetta of the Resolver-TM- System
and Server Software if requested by DuPont.

          5.4 TECHNICAL SUPPORT. Technical support as used in this Agreement
means bug fixes, trouble shooting, and minor clarifications on use of the
Resolver-TM- System, and does not include any modifications to the Resolver-TM-
Software. Technical support does not include training or customization of the
Resolver-TM- Software.

          5.5 MAINTENANCE. Maintenance as used in Article 5 includes any work
done by Rosetta to keep the Server running properly while the Server is on
Rosetta premises including, if required, (1) Server database backups and
restores, (2) installation of Resolver-TM- Software updates and upgrades on the
Server, (3) labor associated with Server hardware repair, and (4) initial Server
hardware configuration. Maintenance as used in Article 5 does not include
installation of Resolver-TM- Client Software on DuPont's desktop computers,
installation of Server software after delivery of the Server to premises,
DuPont's or customization of the Resolver-TM- System for DuPont's needs.

          5.6 SERVICE. Time spent by Rosetta under this Agreement that does not
qualify as technical support or maintenance such as customization of the
Resolver-TM- System for DuPont's needs shall be considered service. At the
beginning of Stage 1, DuPont shall have a credit of [***] of service. This
credit of [***] is available to DuPont during Stages 1, 2, and 3 of this
Agreement and such credit shall expire at the end of Stage 3. Any time spent
by

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -12-
<PAGE>

Rosetta that exceeds the [***] of credited service shall be invoiced to DuPont
at [***]. In the event that a Rosetta employee or agent must make a service
call to DuPont's premises, reasonable expenses for travel and lodging of such
employee or agent will be paid by DuPont. Travel time, per se, shall not be
counted toward the credit.

                            ARTICLE 6 -- COMPENSATION

          6.1 DuPont shall pay directly to Rosetta [***] ("Agreed Price") plus
any applicable fees or taxes for the rights and licenses provided herein and
for the other goods and services provided hereunder. The Agreed Price shall be
guaranteed and it shall be non-refundable except as provided in Section 9.3.
[***] of the Agreed Price shall be paid within [***] of receipt of an invoice
by DuPont following the Effective Date, [***] of the Agreed Price shall be
paid within [***] days of receipt of an invoice by DuPont for Stage 1
deliverables described in Sections 5.1.1.1, 5.1.1.2, 5.1.1.3, and 5.1.1.6,
and the balance of the Agreed Price shall be paid within [***] days of
receipt of an invoice by DuPont of Stage 3 deliverables described in Sections
5.3.1.1 and 5.3.1.2.

          6.2 The amount set forth in Section 6.1 is comprised of the
following:

          [***]

          6.3 In the event DuPont shall from time to time elect to extend the
term of Rosetta's obligations pursuant to Section 7.1.2, DuPont shall, upon each
such election, pay an amount not to exceed [***] of the then existing list
price of the Resolver-TM- Software license.

                 ARTICLE 7 - TERM AND TERMINATION OF THE PROGRAM

          7.1      TERM.

          7.1.1 The term ("Term") of this Agreement shall begin on the
Effective Date and shall terminate upon the earlier of (1) one (1) year after
the initiation of Stage 3, (2) the date to which this Agreement is extended
in accordance with Section 7.1.2, or (3) the date this Agreement is
terminated pursuant to Section 7.2. Provisions of this Agreement which, by
their nature, should survive termination such as, but not limited to Sections
3.1.2, 3.1.4, 3.6, 3.8, 3.9, or the

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -13-
<PAGE>

obligations of Articles 8 shall survive termination of this Agreement.

          7.1.2. DuPont will have the right and option, exercisable in
writing at any time during the three (3) month period immediately preceding
the then current date on which this Agreement is to expire, to notify Rosetta
that DuPont elects to extend the term of Rosetta's obligations to provide
Software upgrades, and maintenance and support services related to the
Resolver-TM- System for one additional year. In the event of any such
election by DuPont, DuPont shall thereupon promptly pay to Rosetta the amount
set forth in Section 6.3 hereof. The Parties acknowledge and agree that they
will negotiate in good faith an amendment and restatement to this Agreement
upon the first exercise by DuPont of its election to extend Rosetta's
obligations hereunder, taking into account completion of Stages 1, 2, and 3,
and incorporating such terms and conditions that are ordinary and customary
for maintenance and support contracts for software similar in scope and
complexity to the Resolver-TM- Software.

          7.2 NOTICE OF DEFAULT, CURE PERIOD, AND TERMINATION. If a Party
defaults in the performance of its obligations under this Agreement, the
other Party may send a written notice to the defaulting Party describing such
default or defaults. The defaulting Party shall cure the default or defaults
described in the notice within thirty (30) days after the giving of such
notice, unless it is not technically feasible to cure the default within such
thirty (30) days, in which case the defaulting Party (i) shall prepare and
submit to the non-defaulting Party within such thirty (30) days period a
mutually agreeable plan to cure the default and (ii) shall proceed to cure
the default under such plan, PROVIDED, HOWEVER, in the event the default is
in respect of DuPont's obligations under Section 6.1 hereof, such default
shall be cured within seven (7) days after the giving of such notice. If the
Parties do not agree upon a plan to cure the default, or if the Party in
default fails to cure its default or defaults within the time period or
periods specified in the preceding sentence, the other Party may terminate
the Program by delivering a notice of termination to the defaulting Party.

                          ARTICLE 8 -- CONFIDENTIALITY

         8.1 EXCHANGE AND CREATION OF CONFIDENTIAL INFORMATION. The Parties
anticipate the need to disclose, exchange, and create Confidential Information
during the Program. The Parties also recognize that an employee, consultant or
representative of a Party in visiting the premises of another Party may be given
access to areas of the premises of such other Party where such employee,
consultant or representative may observe or overhear Confidential Information
that has not been marked or stated to be confidential. As used in this Article
8, the Party that discloses Confidential Information to the other Party as
described in Section 1.4 shall be called the Disclosing Party with respect to
such information, and the Party that receives Confidential Information from the
Disclosing Party as described in Section 1.11 shall be called the Receiving
Party with respect to such information. If an employee, consultant, or
representative of one Party creates or develops information jointly or in
conjunction with an employee, consultant, or representative of another Party,
and if either Party notifies the other Party that it has designated such
information as Confidential Information or a reasonable person would treat such
information as confidential or proprietary, the information will be considered
and treated as Confidential Information hereunder; each Party then shall have
the rights of a Disclosing Party and the responsibilities of a Receiving Party.

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -14-
<PAGE>

          8.2 MARKING, DESIGNATION, AND TRANSMITTAL OF CONFIDENTIAL
INFORMATION. Each Party that wishes to protect its Confidential Information
shall take precaution (a) to mark any document containing Confidential
Information with an appropriate legend, such as "Confidential" or
"Proprietary" or other similar marking, before giving it to another Party,
(b) to advise the other Party at the time of an oral or visual disclosure of
Confidential Information that such information is confidential, (c) to
prepare a written summary of all such Confidential Information that is
disclosed orally or visually and (d) to send such summary to the other Party
within thirty (30) days of the oral or visual disclosure confirming that such
information previously disclosed orally or visually is to be considered
confidential. When transmitting Confidential Information via encrypted email,
the Disclosing Party shall send a copy of the encrypted email message to the
Program Contact for the Receiving Party and a copy of the encrypted email
message to its own Program Contact. The Program Contact for each Party shall
maintain copies of all encrypted email messages containing Confidential
Information that are sent and that are received by such Party for a period of
five (5) years from the date of receipt. This provision shall not be read to
limit the definition of Confidential Information set forth in Section 1.2.

          8.3 ACKNOWLEDGEMENT OF TRADE SECRETS. DuPont acknowledges that the
Software contains valuable trade secrets and confidential information owned by
Rosetta including, but not limited to, the development status of the Software,
the functionality of the Software, the appearance, content and flow of the
Software's user interface, the content of the Software's documentation and other
information, and data related and ancillary to the Software. All of such trade
secrets and information are considered Confidential Information as that term is
used in this Agreement.

          8.4 PROTECTION OF CONFIDENTIAL INFORMATION. Each Receiving Party shall
use at least the same degree of care in protecting the Disclosing Party's
Confidential Information as it uses to protect its own Confidential Information.
Each Party represents that it maintains a reasonable system to protect its own
Confidential Information and the Confidential Information that it receives from
others. Each Party further represents and warrants to the other Party that its
employees, consultants, and representatives who will perform any work under this
Agreement and who will have access to Confidential Information will be subject
to a valid, binding and enforceable agreement to maintain the confidentiality of
Confidential Information and to fulfill the obligations with respect to
Confidential Information set out in this Article. Each Party shall take
reasonable precaution to prevent employees, consultants, or representatives of
another Party or third parties from (a) receiving any document containing
Confidential Information that has not been marked with an appropriate legend and
(b) observing or overhearing Confidential Information that has not been marked
or stated to be confidential.

          8.5 RESTRICTIONS ON DISCLOSURE OF CONFIDENTIAL INFORMATION. The
Receiving Party shall not disclose any Confidential Information that it received
from the Disclosing Party, without prior written permission of the Disclosing
Party, to any person other than to its employees, and consultants, and
representatives who have a need to know such information to carry out their
duties or activities in connection with the Program or as otherwise authorized
by this Agreement; provided, however, that any consultant of the Receiving Party
to whom

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -15-
<PAGE>

Confidential Information is disclosed, must be obligated by written agreement to
give the same protection to the Confidential Information as is provided herein,
or have a similar obligation to the Receiving Party to maintain confidential
information in confidence. If a Receiving Party is required by judicial or
administrative process to disclose Confidential Information of the Disclosing
Party, such Receiving Party shall notify such Disclosing Party in writing and
allow the Disclosing Party reasonable opportunity to oppose such process or
limit the disclosure of Confidential Information.

          8.6 EXCLUSIONS. A Receiving Party may disclose information even though
it may be considered Confidential Information of a Disclosing Party in
connection with a judicial proceeding requiring such disclosure provided that
the Disclosing Party has adequate notice of such proceeding and an opportunity
to object to or limit the disclosure, and provided that the disclosure of
Confidential Information is limited to what is required as mutually determined
by the Receiving Party and the Disclosing Party.

          8.7 TREATMENT OF PREVIOUS DISCLOSURES. If the Parties have
communicated Confidential Information pertinent to the Early Access Program to
each other pursuant to Confidential Disclosure Agreements and/or Non-Disclosure
Agreements, prior to the Effective Date, all such Confidential Information
transmitted, received, or exchanged will be governed by this Agreement, which
shall supersede any such other agreements in their application to Confidential
Information relating to the Program.

          8.8 SURVIVAL AND EXPIRATION. The obligations of non-disclosure and
restrictions on use contained in this Article 8 shall survive for a period of
five (5) years from the expiration or termination of the remaining provisions
of this Agreement.

                   ARTICLE 9 -- REPRESENTATIONS AND WARRANTIES

          9.1 WARRANTIES BY EACH PARTY. Each Party represents and warrants to
the other Party that:

          9.1.1 such Party has full corporate right, power, and authority to
enter into this Agreement and to perform the acts required of it hereunder;

          9.1.2 the execution of this Agreement by such Party, and the
performance by such Party of its obligations and duties hereunder do not and
will not violate any agreement to which such Party is a party or by which it is
otherwise bound;

          9.1.3 when executed and delivered by such Party, this Agreement will
constitute the legal, valid, and binding obligation of such Party, enforceable
against such Party in accordance with its terms; and

          9.1.4 such Party acknowledges that the other Party makes no
representations, warranties, or agreements related to the subject matter of this
Agreement that are not expressly provided for in this Agreement.

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -16-
<PAGE>

          9.2 WARRANTY OF Y2K COMPLIANCE. Rosetta warrants that the
Resolver-TM- Software is Year 2000 Compliant. "Year 2000 Compliant" shall mean
that dates before, on, or after January 1, 2000, encountered and/or processed
by the Resolver-TM- Software will be correctly recognized, calculated, sorted,
stored, displayed, and/or otherwise processed within the Resolver-TM- Software.
This warranty shall not be subject to any disclaimer or exclusion of warranties
made in this Agreement pursuant to Section 9.3, except that this warranty shall
not be construed to apply to any of the other components of the Resolver-TM-
System including, but not limited to, the hardware and other software, such as
Server software which is not Resolver-TM- Server Software and third party
software, provided under this Agreement.

          9.3 ACKNOWLEDGMENT BY DUPONT; DISCLAIMER OF OTHER WARRANTIES.
DuPont and Rosetta agree that the Software is provided "AS IS" and that
Rosetta makes no warranty as to the Software. DuPont acknowledges and agrees
that (i) the Software is not a product that has been commercially released
for sale by Rosetta, (ii) the Software is not in final form and may contain
errors, design flaws, or other problems, (iii) the Software is not expected
to function error-free upon installation, and it is expected and anticipated
that further testing, modification, and development will be necessary to make
the Software fully functional, (iv) it may not be possible to make the
Software fully functional, (v) use of the Software may result in unexpected
results, loss of data, project delays, or other unpredictable damage or loss
to DuPont and (vi) Rosetta is under no obligation to release and/or offer for
sale the commercial version of the Software, and Rosetta has the right to
unilaterally abandon development of the Software, all at any time and in each
case without any obligation or liability to DuPont, provided, however, that
if Rosetta abandons development of the Software during a one (1) year period
beginning with the initiation of Stage 1, Rosetta shall refund to DuPont the
full amount paid to date by DuPont excluding the amounts paid and owed under
Sections 6.2.2, 6.2.3, 6.2.4, and 6.2.5. ROSETTA DISCLAIMS ALL WARRANTIES,
EXPRESS OR IMPLIED, OTHER THAN THOSE EXPRESSLY SET FORTH IN SECTIONS 9.1 AND
9.2 HEREOF INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF NON-INFRINGEMENT,
PATENTABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH
RESPECT TO THE RESOLVER-TM- SYSTEM AND RESOLVER-TM- SOFTWARE INCLUDING, BUT
NOT LIMITED TO, ALL HARDWARE AND ALL OTHER SOFTWARE SUCH AS SERVER SOFTWARE
AND THIRD PARTY SOFTWARE PROVIDED UNDER THIS AGREEMENT. FURTHERMORE, ROSETTA
EXPRESSLY DISCLAIMS THE WARRANTY MADE IN SECTION 9.2 WITH RESPECT TO THE
COMPONENTS OF THE RESOLVER-TM- SYSTEM OTHER THAN THE RESOLVER-TM- SOFTWARE
INCLUDING, BUT NOT LIMITED TO, ALL HARDWARE AND ALL OTHER SOFTWARE SUCH AS
SERVER SOFTWARE WHICH IS NOT RESOLVER-TM- SERVER SOFTWARE AND THIRD PARTY
SOFTWARE PROVIDED UNDER THIS AGREEMENT.

            ARTICLE 10 -- DISCLAIMERS AND LIMITATION OF LIABILITIES

         10.1 INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS. Rosetta disclaims
any representation or warranty that the technology, information, know-how, data,
software, user documentation, or processes disclosed or furnished to DuPont or
conceived, developed, or used in the Program does not or will not infringe any
Intellectual Property Rights of any third party

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -17-
<PAGE>

who is not a party to this Agreement. Each Party shall, however, notify the
other Party promptly in writing if such Party has a reasonable basis for
believing that any such technology, information, know-how, data, or process, or
that any product that incorporates any such technology or that is made using any
such process would infringe any Intellectual Property Right of a party who is
not a party to this Agreement. This Section 10.1 shall not be interpreted to
place an affirmative duty on any Party to perform a patent search or other
review of intellectual property of a third party to determine if it is
infringing any Intellectual Property Right of another Party or a party who is
not a Party.

          10.2 LIMITATION OF LIABILITIES. NO PARTY SHALL UNDER ANY CIRCUMSTANCES
BE LIABLE TO ANOTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL
DAMAGES, LOSSES, LIABILITIES, COSTS, OR EXPENSES (INCLUDING, BUT NOT LIMITED TO,
LOSS OF PROFITS, GOODWILL, REVENUE, OR BUSINESS) RESULTING FROM OR IN ANY WAY
RELATED TO THIS AGREEMENT, OR TERMINATION OF THIS AGREEMENT, OR ARISING OUT OF
OR ALLEGED TO HAVE ARISEN OUT OF (I) BREACH OF THIS AGREEMENT, (II) THE FAILURE
BY ANY PARTY TO DEVOTE THE RESOURCES OR EFFORT SPECIFIED IN THIS AGREEMENT,
(III) THE FAILURE BY ANY PARTY TO COMPLY WITH THE EXPRESS CONDITIONS SPECIFIED
IN THIS AGREEMENT, OR (IV) ANY EVENT RELATED TO THE MAKING OR PERFORMANCE OF
THIS AGREEMENT. THIS LIMITATION APPLIES REGARDLESS OF WHETHER SUCH DAMAGES ARE
SOUGHT BASED ON BREACH OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, STRICT
LIABILITY, OR ANY OTHER LEGAL OR EQUITABLE THEORY.

          10.3     INFRINGEMENT.

          10.3.1 DuPont and Rosetta agree that Rosetta will indemnify DuPont
against and will defend, at its own expense, all proceedings, suits, and claims
against and/or affecting DuPont or any of its officers, directors, or employees
alleging the infringement, breach or violation of any Intellectual Property
Rights of any third party covering, or alleged to cover, the Software, in the
form furnished or as subsequently modified by Rosetta. Rosetta agrees to defend
any such proceeding, suit, or claim, and to pay all costs, fees, and expenses
including, without limitation, all reasonable attorneys' fees and other costs,
incurred by DuPont and its officers, directors, agents or employees in
connection with the defense of any such proceeding, suit, or claim, provided
that:

                   (i) Rosetta will be given written notice of all claims of any
          such infringement or violation and of any suits or claims brought or
          threatened against DuPont;

                   (ii) Rosetta will be given full authority to assume control
          of the defense thereof through its own counsel at its sole expense but
          will not compromise or settle any suits or claims without the express
          prior written consent of DuPont, provided that such consent will not
          be unreasonably withheld or delayed;

                   (iii) DuPont will reasonably cooperate with Rosetta in the
          defense of such

                                      -18-
<PAGE>

          proceeding, suit, or claim at Rosetta's sole expense; and

                   (iv) the total expense that Rosetta shall be obligated to
          bear and pay under this Section 10.3.1 shall not exceed [***], the
          amount of the Resolver-TM- Software license paid by DuPont.

                   10.3.2 DuPont will indemnify Rosetta against all liabilities
          and costs, including reasonable attorneys' fees, for defense and
          settlement of any and all claims against DuPont or Rosetta in the
          event an allegation of infringement or violation of Intellectual
          Property Rights of a third party is caused by (i) modification of the
          Software by DuPont, (ii) any infringement caused by DuPont's use or
          maintenance of the Software which conflicts with the terms and
          conditions of this Agreement, and (iii) DuPont's willful use of the
          Software after receipt of notice of infringement.

                   ARTICLE 11 -- DISPUTES BETWEEN THE PARTIES

         11.1 SCOPE AND PURPOSE OF THIS ARTICLE. The purpose of this Article
11 is to set forth the procedures pursuant to which the Parties intend in
good faith to resolve any and all disagreements and disputes between the
Parties arising under or related to this Agreement or its making, or the
activities of the Parties in connection with the Program (collectively,
"Disputes"). The Parties shall follow these procedures fully and exhaustively
before initiating any litigation to resolve any Dispute. However, nothing
herein shall prevent a Party from filing suit seeking equitable relief
(mandatory or prohibitive) to prevent what it perceives as imminent,
irreparable harm or to compel a Party to specifically perform in accordance
with this Article 11; provided, that if such relief is granted, the Parties
will stipulate that any further proceedings in such suit shall be stayed
pending the completion of the procedures set forth herein. These procedures
do not apply to any claims by unrelated parties. The Parties stipulate that
the running of any applicable statute of limitations shall toll effective
upon the first notice given under Section 11.2 until thirty (30) days after
the completion of the process provided in Section 11.3.

          11.2 NOTICE OF DISPUTE. A Party that perceives a Dispute with the
other Party subject to this Article 11 may notify the other Party in writing
of any Disputes that it wants resolved ("Notifying Party"). The Notifying
Party shall include in the notice a detailed statement of the Disputes and a
summary of the evidence and arguments supporting the position asserted. The
other Party ("Responsive Party") shall respond to the notice within ten (10)
business days after receipt thereof and may include with its response a
cross-notice of any Disputes that the Responsive Party wants resolved. If a
Responsive Party raises an additional Dispute, the Notifying Party shall then
respond to such cross-notice within seven (7) business days after receipt of
the Responsive Party's cross-notice. Notwithstanding Section 3.9, all
notices, cross-notices and responses shall be in writing and sent by
facsimile with a confirming copy sent by first class mail.

          11.3 UNAIDED NEGOTIATIONS BETWEEN THE PARTIES. Initially the
Program Contacts and the General Managers of the business unit participating
in the Program shall meet at a mutually acceptable time and place within
fifteen (15) businsss days after delivery of the final response, and
thereafter as often as they deem necessary, to exchange relevant information
and attempt to

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -19-
<PAGE>

resolve the dispute. If the matter is not resolved by these Managers within
thirty (30) business days of receipt of the Notifying Party's first written
notice, or if such Managers fail to meet within fifteen (15) business days
after delivery of the final response, the Dispute shall be referred to the
senior executives who have responsibility for the respective organizations
involved in the Dispute and who have full and final authority to settle the
Dispute. These senior executives shall likewise meet, with or without the
respective Business Managers and Program Managers, at a mutually acceptable
time and place within ten (10) business days after such referral, and
thereafter as often as they reasonably deem necessary, to exchange
information and attempt to resolve the Dispute. All meetings to be held under
this Section 11.3 may be held in person, or may be held by means of telephone
or similar communications equipment.

          11.4 LITIGATION. If, after completing the above procedures set out in
Section 11.3, the Parties involved in the Dispute have not resolved fully all
Disputes, any Party involved in an unresolved Dispute may file suit in a United
States District Court if the dispute involves a federal question and the other
requirements for federal jurisdiction are met, or in a State Court if the
dispute involves only non-federal questions or the requirements for federal
jurisdiction are not met. The venue for a suit filed by DuPont shall be Seattle,
Washington, and the venue for a suit filed by Rosetta shall be Wilmington,
Delaware.

          11.5 GOVERNING LAW. This Agreement and all questions, claims,
disputes, remedies or procedural matters relating to Disputes under this
Agreement shall be interpreted in accordance with and governed exclusively by
the laws of the State of Delaware, U.S.A., without regard to the principles of
conflicts of law.

                           ARTICLE 12 -- MISCELLANEOUS

          12.1 LEGAL STATUS OF THE PARTIES AND THE PROGRAM. Each Party is an
independent contractor and will act as such in accordance with the terms of this
Agreement in performing its respective obligations under this Agreement. This
Agreement is not intended to create, nor shall the activities of the Parties or
the Program be construed to create, a joint venture, partnership, or other
formal business organization. No Party shall represent to any third party that
this Agreement creates, or that the Program is, a joint venture, partnership, or
other formal business organization. Nothing herein shall be construed as
providing for the sharing of profits or losses. Except as expressly provided
herein, no Party can bind any other Party or create any relationship of
principal or agent. Except as expressly provided herein, nothing in this
Agreement shall grant to any Party the right to make future commitments of any
kind for or on behalf of the other Party. No employee of one Party shall be
deemed to be the employee of another Party by virtue of this Agreement. No Party
shall have any liability for any activities of any other Party by virtue of this
Agreement.

          12.2 NO THIRD PARTY BENEFICIARIES. This Agreement is intended for the
sole benefit of the Parties hereto, and unless expressly provided herein, no
rights or powers shall arise hereunder in favor of any third party.

          12.3 FORCE MAJEURE. The failure of any Party to perform hereunder as a
result of governmental action, laws, orders, or regulations, or as a result of
events, such as war, acts of

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -20-
<PAGE>

public enemies, fires, floods, earthquakes, acts of God or any causes of like
kind beyond the reasonable control of such Party is excused for so long as such
cause exists, but only to the extent such failure is caused by such law, order,
regulation, or event.

          12.4 EXPORTS. Each Party hereto shall be responsible for ensuring its
compliance with the laws and regulations of the United States government
relating to the export of goods and technology from the United States, and the
Party receiving technical information from another Party hereby agrees to comply
fully with the United States Export Administration Act and regulations
promulgated thereunder from time to time by the United States government with
respect to that technical information.

          12.5 ASSIGNMENT. Neither Party may assign this Agreement nor any of
its rights or obligations hereunder without the prior written consent of the
other Party, except that a Party may assign its rights and obligations, without
the consent of the other Party, as part of an assignment of the entire
Agreement, in connection with (i) a change of the state of incorporation of a
Party, or (ii) a merger of a Party into its parent corporation, (iii) the
spin-out of the business with which this Agreement is associated into a wholly
owned corporation of a Party, (iv) the spin-out of the business with which this
Agreement is associated into a separate entity, (v) the subsequent merger of any
such wholly owned corporation or separate entity into another entity or (vi) the
sale of substantially all the assets of the business unit with which the
agreement is associated. Any permitted assignee shall assume all obligations of
its assignor under this Agreement. No assignment shall relieve any Party of
responsibility for the performance of any accrued obligation that such Party
then has under this Agreement without prior written consent of the other Party.
Any purported assignment by one Party in violation of this Section shall be
voidable by any other Party.

          12.6 RULES OF CONSTRUCTION AND INTERPRETATION. This Agreement shall be
construed and fairly interpreted in accordance with its terms, without any
strict construction in favor of or against either Party. Ambiguities shall not
be interpreted against the drafting Party. Any ambiguities in this Agreement
shall be interpreted in accordance with the objectives stated in the Recitals.
In construing or interpreting this Agreement, the word "or" shall not be
construed as exclusive, and the word "including" shall not be limiting. The use
of the singular or plural form shall include the other form and the use of the
masculine, feminine or neuter gender shall include the other genders. All
captions and headings in this Agreement are for convenience only and shall not
be considered as substantive parts of this Agreement or determinative in the
interpretation of this Agreement.

          12.7 AMENDMENT AND WAIVER. Any provision of this Agreement may be
amended or waived only with the written consent of the parties. Any amendment or
waiver effected in accordance with this Section shall be binding upon the
parties and their respective successors and assigns.

          12.8 SEVERABILITY. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, the Parties agree to renegotiate
such provision in good faith, in order to maintain the economic position enjoyed
by each Party as close as possible to that under the provision rendered
unenforceable. In the event that the Parties cannot reach a mutually

                                      -21-
<PAGE>

agreeable and enforceable replacement for such provision, then (i) such
provision shall be excluded from this Agreement, (ii) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (iii)
the balance of the Agreement shall be enforceable in accordance with its terms.

          12.9 INTEGRATION. This Agreement, together with the Appendices
identified below, contains the entire understanding of the Parties as it relates
to the subject matter hereof and supersedes any prior agreements or
understandings between or among the Parties as to this subject matter:

          12.9.1 Appendix A -- Features for Resolver-TM- Software for Stages 1,
2, and 3

          12.9.2 Appendix B -- Virtual private network specification

          12.9.3 Appendix C -- Specification of desktop computers to be used by
DuPont

          12.10 DISPARAGEMENT. DuPont agrees not to disparage or make negative
comments about Rosetta's personnel, the Resolver-TM- System, or services
provided by Rosetta.

          12.11 COUNTERPARTS. This Agreement may be signed in any number of
counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same instrument.

                            [Signature page follows]

                                      -22-
<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives on the date written below.

DUPONT PHARMACEUTICALS COMPANY               ROSETTA INPHARMATICS, INC.

By /S/                                       By
  ----------------------------                 ----------------------------
                                                      John J. King, II

   DIRECTOR PROCUREMENT                      SR. VICE PRESIDENT
------------------------------               ----------------------------
              Title                                      Title

   10/07/99                                  SEPTEMBER 30, 1999
----------------------------                 ----------------------------
               Date                                        Date

                                      -23-
<PAGE>

      APPENDIX A -- FEATURES OF RESOLVER-TM- SOFTWARE FOR STAGES 1,2, AND 3 7

STAGEL:  FEATURES IN INITIAL FEATURE RELEASE

IMAGE VIEWER
View and interpret images representing primary data for a given profiling
technology.

PLOT VIEWER
A flexible plotting engine for experiments, profiles, and genes with powerful
analytical features to help decision making and the presentation of results.

TABLE VIEWER
View expression data for experiments, profiles, and genes in a customizable
spreadsheet format. Sort & export data for use in other applications. Rearrange,
show, or hide columns to tailor the display to the user's needs.

CORRELATION PLOT VIEWER
Using the Correlation Plot Viewer, pairs of genes, profiles, or experiments in
the user's gene expression database can be quickly compared.

SYNCHRONIZATION
Synchronization refers to the Resolver application's ability to share selected
data among many different tools. Use synchronization to quickly and effectively
visualize and analyze data identified in one tool using a second tool.

ROLE-BASED SECURITY SYSTEM
The role-based security system delivered with the Resolver application provides
row-level access control for all cell lines, tissues, hybridizations, profiles,
and experiments.

PERSISTENT USER PROFILES
Persistent user profiles allow all users to set preferences for the way they use
the Resolver application --table configuration, statistical cutoffs,
highlighting, etc.--and have those same options in place the next time they use
the Resolver, even if the system is accessed using another client machine.

ANNOTATION MANAGERS FOR CELL LINES/TISSUES, NUCLEIC ACID PREPARATIONS (PREPS),
AND HYBRIDIZATIONS (HYBS) The Resolver application includes spreadsheet-like
interfaces and forms for scientists to effectively manage cell lines and
tissues, RNA samples, hybridizations, and experiments tracked within the system.

QUALITY STATISTICS
The Resolver application includes easy-to-understand quality statistics,
including P-values on every gene expression measurement. Using these statistics,
even the subtlest transcriptional responses can be characterized by repeating
expression profiles and combining them into statistically averaged experiments
within the Resolver application.

STAGE 2. SECOND FEATURE RELEASE INCLUDES ALL FEATURES IN INITIAL FEATURE
         RELEASE, PLUS:

ROSETTA ARRAY SEARCH TOOL ("ROAST")
Use ROAST (Rosetta Array Search Tool), to compare one gene, experiment, or
expression profile against others in the database. This tool is analogous to the
BLAST sequence analysis tool.

USER-DEFINED BIOSETS
Use the BioSets features in the Resolver application to group and store
collections of genes or experiments of interest and perform set manipulation on
these groups. Add annotation and comments to BioSets and, if desired, share them
collaboratively with other Resolver users.

<PAGE>

COMMENT SYSTEM
An easy-to-use comment system allows users to add or view comments about genes,
experiments, expression profiles, or BioSets and even respond to comments made
by other users. View comments in hierarchical newsgroup-like format or in table
format.

INSTALINK-- PRODUCTIVITY LINK SYSTEM
Use InstaLink to quickly access bioinfonnatics resources within the Resolver
application, on the World Wide Web, or on the user's Intranet that aid in the
analysis of a particular datapoint within the application. Medline, Entrez, and
other databases can be searched with two clicks using this feature. The user can
add personalized productivity links to Internet and Intranet sites.

STAGE 3. FEATURE-COMPLETE RELEASE INCLUDES ALL FEATURES IN SECOND
                   FEATURE RELEASE, PLUS:

CLUSTER ANALYSIS ENGINE
Analyze gene expression data, and identify co-regulated gene sets and classes of
similar compounds using a high-performance, flexible cluster analysis engine.

CLUSTER TREE VIEWER
Visualize and analyze data from the Cluster Analysis Engine in a compact,
convenient hyperbolic display. Search for genes or experiments of interest, and
zoom, magnify, move, or rotate trees to identify clusters of interest.

SERVER ADMINISTRATION TOOLS
Use these configuration interfaces and control panels to administer and
customize the Resolver application.

*   Resolver is a trademark of Rosetta Inphannatics, Inc.

<PAGE>

      APPENDIX B -- VIRTUAL PRIVATE NETWORK SPECIFICATIONS

    [***]

Electrical

    -  Line Voltage: 100/115/230 VAC
    -  Frequency: 50/60 Hz
    -  Maximum power consumption: 5 amps

Physical

    -  19-rack mount kit
    -  Height: 6" (15.24cm)
    -  Width: 16" (40.64cm)
    -  Length: 16.5" (41.94cm)

Environmental

    -  Operating temperature: 41 degrees, 104 degrees F (5 degrees, 40
       degrees C)
    -  Storage temperature: -40 degrees -158 degrees F (-40 degrees 70
       degrees C)
    -  Relative humidity: 10% 80%, noncondensing

2.  This VPN hardware is configurable to balance security with speed.
Configuration of this hardware to maximum security levels will negatively
affect performance of the Resolver-TM- System available to DuPont.

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

<PAGE>

      APPENDIX C -- DESKTOP COMPUTER MINIMUM SPECIFICATIONS

Minimum Specifications

    300 MHz Pentium II or III Compatible processor
    128 Megabytes of RAM
    20 Megabytes free hard drive space
    Windows 98 or Windows NT Workstation 4.0 SP3+
    Minimum number of displayable colors: 65536
    Minimum monitor resolution: 1024 x 768

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.<PAGE>

                     GENE EXPRESSION COLLABORATION AGREEMENT

         THIS COLLABORATION AGREEMENT (the "Agreement") is entered into as of
October 1, 1999 (the "Effective Date"), by and between ROSETTA INPHARMATICS,
INC., a corporation organized under the laws of the State of Delaware
("Rosetta"), and HEWLETT-PACKARD COMPANY, a corporation organized under the laws
of the State of Delaware.

RECITALS

         A. Rosetta is a developer of new technology, products and services in
the analysis of gene expression and the manufacturing of In-Situ Arrays which
can be used to improve the activities of pharmaceutical and other types of
organizations.

         B. Hewlett-Packard Company is a leading world-wide developer and
supplier of instrumentation, software, supplies and services to customers in
pharmaceutical and other industries including instrumentation, Arrays and
related software and reagents.

         C. Hewlett-Packard Company and Rosetta wish to form a broad
collaboration to design, develop, manufacture, commercialize and use the
Collaborative Products as defined herein.

THE PARTIES THEREFORE AGREE:

1.       DEFINITIONS

         Each of the capitalized terms in this Agreement shall have the meaning
as defined below. Terms defined in singular form shall include the plural form
and vice versa.

         "888 Patent" means U.S. Patent Number 5,777,888 and U.S. Continuation
patent application serial number [***] entitled [***].

         "AFFILIATES" means any company or entity controlled by, controlling, or
under common control with, a Party hereto and shall include without limitation
any company more than fifty percent (50%) of whose voting stock or participating
profit interest is owned or controlled, directly or indirectly, by a Party, and
any company which owns or controls, directly or indirectly, more than fifty
percent (50%) of the voting stock of a Party.

         "AFM" means the version of Hewlett-Packard Company's Accounting and
Finance Manual provided to Rosetta prior to the Effective Date subject to
Article 9 hereof.

         "AGILENT" OR "AGILENT TECHNOLOGIES, INC." means the contracting Party
to this Agreement (other than Rosetta) which at the time of execution of this
Agreement shall be the Hewlett-Packard Company by and through those business
entities within the Hewlett-Packard Company which shall, on or about November 1,
1999, become Agilent Technologies, Inc. Upon the transfer of the Hewlett-Packard
Company assets and personnel dealing with the subject

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

matter of this Agreement to Agilent Technologies, Inc., Agilent shall mean
Agilent Technologies, Inc., a Delaware corporation, and this Agreement shall on
such date be automatically transferred to Agilent Technologies, Inc.

         "AGILENT COLLABORATION INVENTION" means a Collaboration Invention
conceived or made by employees or agents of Agilent solely or jointly other than
with an employee or agent of Rosetta.

         "AGILENT FIELD" means analysis of biological processes in research and
development and clinical trial support outside of the fields of [***].

         "AGILENT KNOW-HOW" means all scientific, technical and engineering
information which (i) Agilent (or its predecessor-in-interest) owns or controls
or to which Agilent (or its predecessor-in-interest) has a license including the
right of sublicense as of the Effective Date or during the Term, (ii) Agilent
uses reasonable efforts to protect as a trade secret, (iii) is incorporated into
or used in the design, development, manufacture, commercialization or use of any
Collaboration Product or Collaboration Product Enhancement and (iv) is not
publicly known or available and is not the subject of a patent application.

         "AGILENT NON-COLLABORATION PRODUCT" means a Non-Collaboration Product
offered to a Third Party by Agilent.

         "AGILENT PATENTS" means (i) all patents including, without limitation,
any substitutions, extensions, reissues, renewals, supplementary protection
certificates and inventors' certificates, which have not been held invalid or
unenforceable by a non-appealable or non-appealed decision of a court of
competent jurisdiction and (ii) all patent applications filed in any
jurisdiction including, without limitation, any provisionals, divisionals,
continuations, and continuations-in-part which, in the case of each of clause
(i) and (ii) above (a) Agilent owns, controls or has a license to (with the
right to sublicense) as of the Effective Date or that cover Inventions or
discoveries that are generated during the Term solely by Agilent as a result of
activities conducted pursuant to or in anticipation of the Business Plan and (b)
generically or specifically claim all or any part of any Collaboration Product
or Collaboration Product Enhancement, or a process used in the design,
development, manufacture, commercialization or use of any Collaboration Product
or Collaboration Product Enhancement, or intermediates used in such processes.
Agilent Patents as of the Effective Date are identified on Exhibit A.

         "AGILENT TECHNOLOGY" means Agilent Patents, Agilent Know-How and
Agilent copyrights relating to any Collaboration Product or Collaboration
Product Enhancement.

         "ARRAY" means a substrate-bound spatially ordered collection of nucleic
acid molecules or nucleic acid analogs that can bind specifically to (a) nucleic
acid molecules or (b) molecules that can bind nucleic acids, where the spatially
ordered collection of such molecules is configured to allow for the simultaneous
probing of a plurality of specific and unique target molecules present in a
single sample mixture.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -2-
<PAGE>

         "BANKRUPTCY EVENT" means an event or circumstance with respect to a
Party whereby such Party (i) ceases conducting its business in the normal
course, (ii) makes a general assignment for the benefit of its creditors, (iii)
petitions, applies for, or suffers or permits with or without its consent the
appointment of a custodian, receiver, trustee in bankruptcy or similar officer
for all or any substantial part of its business or assets or (iv) avails itself
or becomes subject to any proceeding under the U.S. Bankruptcy Code or any
similar state, federal or foreign statute relating to bankruptcy, insolvency,
reorganization, receivership, arrangement, adjustment of debts, dissolution or
liquidation, which proceeding is not dismissed within sixty (60) days of
commencement thereof.

         "BUSINESS PLAN" has the meaning ascribed thereto in Section 3.1 hereof.

         "CANNIBALISTIC TECHNOLOGY" means any Collaboration Product Enhancement,
Agilent New Product or Rosetta New Product, as the case may be, which could
reasonably be expected to displace (or render obsolete or generally
non-competitive) any Collaboration Product and which as a result thereof would
cause Net Revenues associated with the sale or other disposition of such
Collaboration Product by Agilent or Rosetta, as the case may be, to decline in a
material amount over a reasonable period of time.

         "CDNA ARRAY" means an Array in which polynucleotides are (i) used as
probes, (ii) synthesized enzymatically in a template-dependent fashion (e.g., as
PCR products from cDNA templates) and (iii) thereafter deposited on a substrate
in a desired configuration.

         "COHERENT DATABASE" means a specific collection of expression profiles
generated using a set of experimental criteria to which an organism or cell is
subjected that allows identification of similarities and differences in effects
on Gene Expression among compounds, conditions and traits.

         "COLLABORATION INVENTION" means an Invention (other than a Joint
Collaboration Invention or an Invention outside the Agilent Field) conceived or
made or developed solely by one or more employees or agents of either Agilent or
Rosetta while working in the Collaborative Field during the Term and which
Invention is directed to all or any part of a Collaboration Product or
Collaboration Product Enhancement, or a process used in the design, development,
manufacture or use of any Collaboration Product or Collaboration Product
Enhancement or intermediates used in such processes.

         "COLLABORATION MANAGER" shall have the meaning ascribed thereto in
Section 3.2(b) hereof.

         "COLLABORATION PRODUCTS" means Resolver, Arrays, Oligo Set Design
Services, the Pamela System and Rosetta New Products and Agilent New Products
which become Collaboration Products pursuant to Section 2.2 hereof.
Collaboration Products are listed in Exhibit B as amended from time to time.

         "COLLABORATIVE FIELD" means the design, development, manufacture,
commercialization and use of (i) Arrays, (ii) products and services for the
preparation of samples for use with

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -3-
<PAGE>

Arrays, (iii) products and services for the hybridization of samples to Arrays,
(iv) products and services for the extraction of data from Arrays after
hybridization (including, without limitation, scanning systems and Feature
Extraction Software) and (v) products and services principally for the analysis
of data extracted from Arrays, all solely within the Agilent Field.

         "COLLABORATION PRODUCT ENHANCEMENTS" means enhancements or refinements
to Collaboration Products, or a process used in the design, development,
manufacture or use of any Collaboration Product or intermediates used in such
processes which, among other things, may increase the performance, reduce
manufacturing cost, or provide other benefits to one or more Collaboration
Products but which do not add Distinct Functionality, provided, however, for the
purposes of Section 10.3 and 10.4 hereof, Collaboration Product Enhancement
shall mean, to the extent covered by any Rosetta Technology or Agilent
Technology, as the case may be, actual enhancements or refinements to
Collaboration Products, or a process actually used in the design, development,
manufacture or use of any Collaboration Product or intermediates actually used
in such processes which, among other things, may increase the performance,
reduce manufacturing cost, or provide other benefits to one or more
Collaboration Products but which do not add Distinct Functionality.

         "COMMERCIAL SALE" means, with respect to a Collaboration Product, any
sale other than a TAP Sale.

         "COMPONENT" means an element of a Collaboration Product or a device,
method, or chemical used in the design, development, manufacture or use of a
Collaboration Product in the Agilent Field.

         "COMPOUND INTERROGATION" means the storage, retrieval and analysis of
compound effects in non-Array based screening assays using pattern recognition
algorithms, clustering, and sophisticated methods to query such data.

         "CONFIDENTIAL INFORMATION" means any information disclosed by one Party
to the other in connection with activities under this Agreement including, but
not limited to, scientific, technical and engineering information, reports
exchanged between the Parties, marketing and other business plans (including the
Business Plan and the Product Plans), information relating to a Party's
products, sales, financial and corporate affairs, suppliers, customers,
employees, or investors, and other comparable information; provided, that
information will be "Confidential Information" only if it is marked as
confidential at the time of disclosure or, if the material is not in written
form (E.G., orally disclosed), it is treated as confidential at the time of
disclosure .

         "CUSTOM PARTNERING TOOLS" means software developed by Rosetta for a
Third Party in conjunction with a consulting or collaboration arrangement not
otherwise prohibited under this Agreement, provided, however, such software
shall constitute a Custom Partnering Tool only so long as it is not incorporated
into a release of Resolver available either for Commercial Sales or TAP Sales.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -4-
<PAGE>

         "DEVELOPMENT PLAN" means the component of a Product Plan that sets
forth a detailed plan for the development of a particular Collaboration Product
as described in Section 3.2(b) hereof.

         "DIAGNOSTIC PRODUCTS" means products that are subject to regulatory
approval requirements under applicable law, regulations or policies or
regulatory agencies (i.e., PMA or 510(k), or foreign equivalent) or are used for
chemical or biochemical analysis of human samples in a health care setting, such
as a reference laboratory, hospital laboratory, hospital, clinic, doctor's
office or at home, in each case where a patient or his insurance company pays
for such analysis, and veterinary products utilizing similar technology in a
similar setting to the above products.

         "DISTINCT FUNCTIONALITY" means a functionality that a reasonable user
would consider to be meaningfully distinct from the functionality of a then
existing Collaboration Product or Component and which a reasonable person would
consider to be capable of supporting a new or separate revenue stream.

         "EARLY TERMINATION DATE" shall have the meaning ascribed thereto in
Section 10.2 hereof.

         "ENGINEERING RESPONSIBILITY" means, with respect to a Collaboration
Product or as otherwise set forth in Section 4.2 hereof, ultimate responsibility
for deciding upon final specifications and for developing the manufacturing
processes for meeting such specifications.

         "EXCLUDED FIELD" means technology, techniques, products and methods
pertaining to the analysis or use of data or profiles other than as necessary to
use (a) Feature Extraction Software, (b) Resolver in accordance with the terms
of the license granted pursuant to Section 2.6(a)(i), (c) Oligo Set Design
Services or (d) New Products which become Collaboration Products or
Non-Collaboration Products.

          "EXECUTIVE SPONSOR" shall have the meaning ascribed thereto in
Section 3.2(a).

         "EXPIRATION DATE" shall have the meaning ascribed thereto in Section
10.1 hereof.

         "FEATURE EXTRACTION SOFTWARE" means software that is used by or in an
Array scanner and which is limited to extraction of basic feature identity data
(I.E., association of a particular feature with a particular probe) and
intensity data (I.E., reporting of the signal and noise, background, confidence
and associated statistics) from such Array scanner.

         "FINAL ORDER" means an order or judgment of a court of competent
jurisdiction as to which the time to appeal, petition for certiorari, or move
for reargument or rehearing has expired and as to which no appeal, petition for
certiorari, or other proceedings for reargument or rehearing shall then be
pending, or as to which any right of appeal, petition for certiorari or right of
rehearing shall have been waived by a Party hereto or, in the event that an
appeal, writ of certiorari, reargument or rehearing thereof has been sought,
such order or judgement of such court shall have been affirmed by the highest
court to which such order or judgement was

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -5-
<PAGE>

appealed, or from which reargument or rehearing was sought, or certiorari has
been denied, and the time to take any further appeal, petition for certiorari,
or move for reargument or rehearing shall have expired.

         "GAAP" means United States generally accepted accounting principles.

         "GENE EXPRESSION" means, with respect to a field of endeavor,
activities and products directed at identifying which genes of an organism in a
particular biological state or experiment are expressed, and/or the extent to
which such genes are expressed.

         "GENOTYPING" means, with respect to a field of endeavor, activities and
products directed at the determination of the sequence variation which exist in
particular genes or genomic or sequences of a particular organism relative to
some defined population of the organism or related organisms, and the analysis
of such data to correlate sequence information with trait or phenotype.

         "GENOTYPING SOFTWARE" means software that allows storage, retrieval and
analysis of nucleic acid sequence variations which exist in particular genes or
genomic sequences of a particular organism relative to some defined population
of the organism or related organisms and which may contain analysis components
which facilitate the correlation of genomic sequence information with trait or
phenotype.

         "HEALTHCARE MANAGEMENT" means the use of software and other means
developed and intended to analyze data from clinical samples taken in the course
of individual patient care service delivery by a health-care provider in a
commercial setting. Healthcare Management Software does not include software
developed for use in research or clinical trial programs.

         "HR-1 AGREEMENT" means the Collaboration Agreement between
Hewlett-Packard Company and Rosetta Inpharmatics, Inc., signed on behalf of
Rosetta on September 14, 1998.

         "INKJET PATENTS" means the patent applications listed in Exhibit C
attached hereto, and all continuations, continuations-in-part, divisions, and
renewals thereof, all foreign counterparts thereof, and all U.S. or foreign
patents that may be granted thereon, and all reissues and extensions thereof,
and the inventions therein, to the extent that (a) Rosetta owns, controls or has
a license to any of the foregoing (with the right to sublicense) as of the
Effective Date or during the Term and (b) the foregoing generically or
specifically claim all or any part of any Collaboration Product, Collaboration
Product Enhancement or a process used in the design, development, manufacture,
commercialization or use of any Collaboration Product, Collaboration Product
Enhancement, or intermediates used in such processes.

         "INKJET TECHNOLOGY" means Inkjet Patents and Rosetta Know-How relating
to the Inkjet Patents.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -6-
<PAGE>

         "IN SITU ARRAY" means an Array in which oligonucleotides or
oligonucleotide analogs are used as probes and synthesized on a substrate from
individual nucleotides or nucleotide analogs.

         "INVENTION" means anything that is potentially patentable under the
patent law of the United States (Title 35, U.S. Code Section 101 ET SEQ.).

         "JOINT COLLABORATION INVENTION" is an Invention conceived or made
jointly by one or more employees or agents of Rosetta and one or more employees
or agents of Agilent during the Term and which Invention (other than an
Invention within the Excluded Field) is directed to all or part of a
Collaboration Product, or Collaboration Product Enhancement, or a process used
in the design, development, manufacture or use of a Collaboration Product, or
Collaboration Product Enhancement or intermediates used in such processes.

         "KOREA" means, collectively, the Republic of Korea and the
Democratic People's Republic of Korea.

         "MANUFACTURING PLAN" means the component of a Product Plan that sets
forth a detailed plan for the manufacturing of a Collaboration Product as set
forth in Section 5.2(a) hereof.

         "MARKETING PLAN" means the component of a Product Plan that sets forth
a detailed plan for the marketing, sales and support of a Collaboration Product
as set forth in Article 3 hereof.

         "NET REVENUES" means the amount invoiced by Agilent or Rosetta, as the
case may be, or their respective Affiliates or Third Party sublicensee(s), as
applicable, for the sale or other disposition to a Third Party of a
Collaboration Product, less (i) normal and customary trade discounts and
credits, (ii) freight, insurance, sales, use, value added and similar taxes or
duties imposed on the sale or other disposition and included in the gross amount
invoiced, and (iii) currency translation adjustments (if applicable).

          "NON-COLLABORATION PRODUCT" shall have the meaning ascribed thereto in
Section 2.2(a)(iv) or Section 2.2(b)(iv) as the context may require.

         "OLIGO SET DESIGN SERVICES" means consulting services provided by a
Party relating to the choice of probe sequences and their arrangement on Arrays,
which consulting services may include use of Pamela-Resident Set Design Software
or a Component thereof.

         "OLIGO SET DESIGN PATENTS" means the patent applications listed in
Exhibit D attached hereto, and all continuations, continuations-in-part,
divisions, and renewals thereof, all foreign counterparts thereof, and all U.S.
or foreign patents that may be granted thereon, and all reissues and extensions
thereof, and the inventions therein, to the extent that (a) Rosetta owns,
controls or has a license to any of the foregoing (with the right to sublicense)
as of the Effective Date or during the Term and (b) the foregoing generically or
specifically claim all or any part of any Collaboration Product, Collaboration
Product Enhancement or a process used in the design, development, manufacture,
commercialization or use of any Collaboration Product, Collaboration Product
Enhancement, or intermediates used in such processes.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -7-
<PAGE>

         "OLIGO SET DESIGN TECHNOLOGY" means Oligo Set Design Patents and
Rosetta Know-How relating to the Oligo Set Design Patents.

         "OLIGO DEPOSITED ARRAY" is an Array in which oligonucleotides or
oligonucleotide analogs are (i) used as probes, (ii) synthesized in a
template-independent fashion and (iii) thereafter deposited on a substrate in a
desired configuration.

         "PAMELA SYSTEM" means the instrument systems and Components offered by
or in cooperation with Agilent which are used in the performance or automation
of steps in the processing or use of Arrays including [***].

         "PAMELA-RESIDENT SET DESIGN SOFTWARE" means the oligo set design
software developed by Agilent, if any, which is bundled with the Pamela System
and is adapted for use by an end user of a Pamela System for design capabilities
in respect of the choice and location of probes, together with such other
functions and capabilities as may be incorporated therein from time to time by
the Parties in accordance with Section 2.9.

         "PARTY" and "PARTIES" means Agilent and/or Rosetta as the context
requires.

         "POPULATED DATABASES" means sets of pre-compiled data populating a
database, including databases populated with Gene Expression profiles. The
Parties understand and agree that sets of pre-compiled data may be created using
Resolver, but in no event will a Populated Database be included within Resolver.

         "PRODUCT MANAGER" shall have the meaning ascribed thereto in Section
3.2(c) hereof.

         "PRODUCT PLAN" means, with respect to a Collaboration Product, the plan
established by the Parties pursuant to Article 3 of this Agreement. The Product
Plan shall include a Development Plan, a Manufacturing Plan and a
Marketing/Sales/Support Plan.

         "PROTEOMICS" means the analysis of biological cells focused on or using
proteins, peptides or amino acids (excluding the analysis of proteins, peptides
or amino acids that bind to nucleic acid arrays).

         "RELATED FINANCING DOCUMENTS" means, collectively, the Stock Purchase
Agreement, and the Fifth Amended Investors Rights Agreement , the Standstill
Agreement and the Voting Agreement (in each case as defined in the Stock
Purchase Agreement).

         "RESOLVER" means Rosetta's software package with the features set forth
in Exhibit E (as modified from time to time) which has as its principal function
the analysis of expression profiles of unknown compounds, conditions and traits
by determining similarities and differences with the expression profiles of
known compounds, conditions and traits stored within a Coherent Database and
which has a database architecture for the storage, retrieval and analysis of
high throughput Gene Expression data. Resolver may also include a "plug and
play" ability to import

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -8-
<PAGE>

Gene Expression data compiled from other Gene Expression software platforms and
modules developed by either Party to allow for extensions and add-ons, as well
as provision for both horizontal and vertical integration. [***]

         "RESOLVER PLATFORM" means certain Third Party computer hardware and
software configurations necessary for Resolver operation.

          "ROSETTA COLLABORATION INVENTION" means a Collaboration Invention
conceived or made by employees or agents of Rosetta solely or jointly other than
with an employee or agent of Agilent.

         "ROSETTA KNOW-HOW" means all scientific, technical and engineering
information which (i) Rosetta owns or controls or to which Rosetta has a license
including the right of sublicense as of the Effective Date or during the Term,
(ii) Rosetta uses reasonable efforts to protect as a trade secret, (iii) is
incorporated into or used in the design, development, manufacture,
commercialization or use of any Collaboration Product or Collaboration Product
Enhancement and (iv) is not publicly known or available and is not the subject
of a patent application.

         "ROSETTA NON-COLLABORATION PRODUCT" means a Non-Collaboration Product
offered to a Third Party by Rosetta.

         "ROSETTA PATENTS" means all patents including, without limitation, any
substitutions, extensions, reissues, renewals, supplementary protection
certificates and inventors' certificates, which have not been held invalid or
unenforceable by a non-appealable or non-appealed decision of a court of
competent jurisdiction and (ii) all patent applications filed in any
jurisdiction, including, without limitation, any provisionals, divisionals,
continuations, continuations-in-part, which, in the case of each of clause (i)
and (ii) above (a) Rosetta owns, controls or has a license to (with the right to
sublicense) as of the Effective Date or that cover Inventions or discoveries
that are generated during the Term solely by Rosetta as a result of activities
conducted pursuant to or in anticipation of the Business Plan and (b) which
generically or specifically claim all or part of any Collaboration Product or
Collaboration Product Enhancement, or a process for use in the design,
development, manufacture, commercialization or use of any Collaboration Product
or Collaboration Product Enhancement or intermediates used in such processes.
Rosetta Patents as of the Effective Date are identified on Exhibit F.

         "ROSETTA TECHNOLOGY" means Rosetta Patents, Rosetta Know-How and
Rosetta copyrights relating to any Collaboration Product or Collaboration
Product Enhancement.

         "ROYALTY BEARING PORTION" means, when used in connection with the
Pamela System, the Components thereof other than those sourced from a Third
Party and offered in the Pamela System on a marginal value added basis
(determined in reference to Agilent) and, when used in connection with Resolver,
any separately priced Component or Components thereof which incorporate Agilent
Technology.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -9-
<PAGE>

         "SHARED COMMERCIAL REVENUES" means Net Revenues from Commercial Sales
of Resolver (and support and/or maintenance agreements in respect thereof),
provided, however, Shared Commercial Revenue shall not include revenues from (i)
the sale by Rosetta of consulting services and (ii) the sale or other
disposition in Commercial Sales by Rosetta or Agilent, as the case may be, of
the Resolver Platform, associated maintenance and support contracts for the
Resolver Platform and services related to the installation of the Resolver
Platform.

         "SHARED DESIGN REVENUES" means Net Revenues from the sale of Oligo Set
Design Services.

         "SHARED TAP REVENUES" means Net Revenues from TAP Sales of Resolver
(and support and/or maintenance agreements in respect thereof), provided,
however, Shared TAP Revenues shall not include revenues from (i) the sale by
Rosetta of consulting services and (ii) the sale or other disposition in TAP
Sales by Rosetta or Agilent, as the case may be, of the Resolver Platform,
associated maintenance and support contracts for the Resolver Platform and
services related to the installation of the Resolver Platform.

         "STOCK PURCHASE AGREEMENT" means that certain Series D Preferred Stock
Purchase Agreement dated as of the date hereof between Agilent and Rosetta.

         "TAP SALES" means a sale of one or more Collaboration Products or
enhancements thereto to a Third Party pursuant to a contract (which may include,
without limitation, a support and/or maintenance agreement) under which the
Third Party, [***]. The Parties reasonably expect as of the Effective Date that
TAP Sales will be made to the Third Parties identified on Exhibit G.

         "TERM" shall have the meaning ascribed thereto in Section 10.1 hereof.

         "THIRD PARTY" means any individual or entity other than Rosetta,
Agilent or Affiliates of either.

         "UNIVERSITY OF WASHINGTON LICENSE AGREEMENT" means the license
agreement between Rosetta and the University of Washington dated as of September
1, 1997, and as amended as of January 28, 1998.

2.       RIGHTS, OBLIGATIONS AND LICENSES

         2.1      RIGHTS AND OBLIGATIONS REGARDING COLLABORATION PRODUCTS

                  (A) RESOLVER. Resolver shall be exclusively offered to Third
Parties by Agilent according to the Product Plan therefor developed by the
Parties hereunder. Agilent shall not, at any time during the Term, directly or
indirectly, sell or offer to sell to Third Parties (i) the Pamela System bundled
with any software for Gene Expression profiling other than Resolver, (ii)

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -10-
<PAGE>

any software functionally similar to, or competitive with, Resolver (iii)
Populated Databases or (iv) consulting services or products (except as expressly
permitted hereunder) related to the operation or use of Resolver, including but
not limited to Populated Databases and Custom Partnering Tools provided,
however, this clause (iv) shall not prohibit services provided under agreements
for TAP Sales and/or Resolver maintenance and support agreements.

                  (b) OLIGO SET DESIGN SERVICES. Oligo Set Design Services shall
be exclusively offered by Agilent to Third Parties according to the Product Plan
therefor developed by the Parties hereunder.

                  (c) ARRAYS. Arrays shall be exclusively offered to Third
Parties by Agilent according to the Product Plan therefor developed by the
Parties hereunder.

                  (d) PAMELA SYSTEM. The Pamela System shall be exclusively
offered to Third Parties by Agilent according to the Product Plan therefor
developed by the Parties hereunder. Rosetta shall not, at any time during the
Term, directly or indirectly, sell or offer to sell to Third Parties any product
competitive with the Pamela System or any Component thereof including, without
limitation, Feature Extraction Software.

         2.2       RIGHTS AND OBLIGATIONS REGARDING NEW PRODUCTS.

                  (a) NEW PRODUCTS DEVELOPED BY ROSETTA. In the event that
Rosetta from time to time during the Term elects to undertake and completes
sufficient research activities in the Collaborative Field related to the
development of a new or improved product or service with Distinct Functionality
(a "Rosetta New Product") and the functionality of such Rosetta New Product has
been scientifically and financially validated by Rosetta in good faith pursuant
to reasonable methodologies, the following procedure shall apply:

                           (i) NOTICE TO AGILENT.  Rosetta shall provide
Agilent with a proposal a ("Rosetta New Product Proposal") which (A) provides
data (scientific and financial) regarding the Rosetta New Product sufficient to
demonstrate that the product or service has Distinct Functionality, (B)
specifically identifies Agilent Technology, if any, incorporated or reasonably
expected to be incorporated in such Rosetta New Product and (C) proposes a
development plan therefor.

                           (ii) FIRST RIGHT OF NEGOTIATION. Agilent shall have
the first right of negotiation for an exclusive arrangement with Rosetta
regarding the Rosetta New Product.

                           (iii) EXERCISE OF RIGHT OF NEGOTIATION. Agilent shall
have one opportunity to exercise its first right of negotiation by providing
Rosetta, within thirty (30) days of Agilent's receipt of the Rosetta New Product
Proposal, an executed letter of intent setting forth the terms and conditions
under which Agilent would agree to participate in the design, development,
manufacture and commercialization of the Rosetta New Product, provided, however,
the Parties understand and agree that if the Rosetta New Product relates to the
design, development, manufacture or use of an Array, the terms and conditions of
any such letter of intent shall, in the event such Rosetta New Product
constitutes an Array not then currently

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -11-
<PAGE>

offered as a Collaboration Product, include, at a minimum, a royalty to be
paid to Rosetta in an amount not less than [***] nor greater than [***] of
the Net Revenues from the sale of such Rosetta New Product.

                           (iv) FAILURE TO REACH AN AGREEMENT. In the event
Agilent does not provide such executed letter of intent within such thirty (30)
day period, or in the event that the Parties cannot within the thirty (30) day
period following Rosetta's receipt of such executed letter of intent reach
agreement on the final terms and conditions of such exclusive arrangement after
negotiations taking into account in good faith each Party's collaborative
interests (including, without limitation, factors such as development, marketing
and sales responsibilities, market sizes, margins, cost of manufacture and price
comparables), Rosetta shall have the right, subject to Section 2.3 hereof, to
continue the design, development, manufacture and commercialization or use of
such Rosetta New Product internally, or to enter into an arrangement with a
Third Party in respect of such Rosetta New Product on terms which, taken as a
whole, are better to Rosetta than the terms specified in any letter of intent
delivered to Rosetta by Agilent in connection with such Rosetta New Product
Proposal. Any such arrangement with a Third Party shall be subject to the terms
of this Agreement relating to licensing of Agilent Technology, if any, contained
therein or used in the design, development, manufacture or commercialization
thereof. Upon the execution of any agreement relating to such arrangement with a
Third Party, the Rosetta New Product shall be deemed a "Non-Collaboration
Product," provided, however, in no event will Non-Collaboration Product include
any product or service which was not included in a Rosetta New Product Proposal.

                           (v) DESIGNATION AS COLLABORATION PRODUCT.  Upon
agreement with respect to the terms and conditions under which the Rosetta New
Product will be exclusively designed, developed, manufactured and commercialized
by the Parties, such Rosetta New Product will be deemed a Collaboration Product
and the Parties shall amend this Agreement to include the agreement of the
Parties related to such Collaboration Product.

                  (b) NEW PRODUCTS DEVELOPED BY AGILENT. In the event that
Agilent from time to time during the Term elects to undertake and completes
sufficient research activities in the Collaborative Field related to the
development of a new or improved product or service with Distinct Functionality
and such product or service is (y) within the areas of Engineering
Responsibility assigned to Rosetta pursuant to Section 4.2(a) hereof or (z)
incorporates or is reasonably expected to incorporate Rosetta Technology (an
"Agilent New Product"), and the functionality of such Agilent New Product has
been scientifically and financially validated by Agilent in good faith pursuant
to reasonable methodologies, the following procedure shall apply:

                           (i) NOTICE TO ROSETTA. Agilent shall provide Rosetta
with a proposal ("Agilent New Product Proposal") which (A) provides data
(scientific and financial) regarding the Agilent New Product sufficient to
demonstrate that the product or service has Distinct Functionality, (B)
specifically identifies Rosetta Technology, if any, incorporates or reasonably
expected to be incorporated in such Agilent New Product and (C) proposes a
development plan therefor.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -12-
<PAGE>

                           (ii) FIRST RIGHT OF NEGOTIATION. Rosetta shall have
the first right of negotiation for an exclusive arrangement with Agilent
regarding the Agilent New Product.

                           (iii) EXERCISE OF RIGHT OF NEGOTIATION. Rosetta shall
have one opportunity to exercise its first right of negotiation by providing
Agilent, within thirty (30) days of Rosetta's receipt of the Agilent New Product
Proposal, an executed letter of intent setting forth the terms and conditions
under which Rosetta would agree to exclusively participate in the design,
development, manufacture and commercialization of the Agilent New Product.

                           (iv) FAILURE TO REACH AN AGREEMENT. In the event
Rosetta does not provide such executed letter of intent within such thirty (30)
day period, or in the event that the Parties cannot within the thirty (30) day
period following Agilent's receipt of such executed letter of intent reach
agreement on the final terms and conditions of such exclusive arrangement after
negotiations taking into account in good faith each Party's collaborative
interests (including, without limitation, factors such as development, marketing
and sales responsibilities, market size, margins, costs of manufacture and price
comparables), Agilent shall have the right, subject to Section 2.3 hereof, to
continue the design, development, manufacture and commercialization or use of
such Agilent New Product internally, or to enter into an arrangement with a
Third Party in respect of such Agilent New Product on terms which, taken as a
whole, are better to Agilent than the terms specified in any letter of intent
delivered to Agilent by Rosetta in connection with such Agilent New Product
Proposal. Any such arrangement with a Third Party shall be subject to the terms
of this Agreement relating to the licensing of Rosetta Technology, if any,
contained therein or used in the design, development, manufacture or
commercialization thereof. Upon the execution of any agreement relating to such
arrangement with a Third Party, the Agilent New Product shall be deemed a
"Non-Collaboration Product," provided, however, in no event will
Non-Collaboration Product include any product or service which was not included
in an Agilent New Product Proposal, provided, further, in no event may any such
Non-Collaboration Product be bundled with a Collaboration Product without the
prior written consent of Rosetta (which consent will not be unreasonably
withheld).

                           (v) DESIGNATION AS COLLABORATION PRODUCT. Upon
agreement with respect to the terms and conditions under which such proposed
Agilent New Product will be exclusively designed, developed, manufactured and
commercialized by the Parties, such Agilent New Product or will be deemed a
Collaboration Product and the Parties shall amend this Agreement to include the
agreement of the Parties related to such Collaboration Product.

         2.3      CANNIBALISTIC TECHNOLOGY.

                  (a) In the event Agilent, with respect to a Rosetta New
Product Proposal, or Rosetta, with respect to an Agilent New Product Proposal,
shall reasonably and in good faith determine that such a New Product Proposal
involves a Cannibalistic Technology, Agilent or Rosetta, as the case may be,
shall have the right by written notice to require that the other cease all
efforts to commercialize the Agilent New Product or the Rosetta New Product, as
the case may be, during the Term.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -13-
<PAGE>

                  (b) If a Collaboration Product Enhancement or idea therefor
developed by a Party would, if incorporated into a product (the "Cannibalizing
Product") for which such Party has Engineering Responsibility, be a
Cannibalistic Technology with regard to a Collaboration Product under the
Engineering Responsibility of the other Party (the "Cannibalized Product"), the
Party with such Collaboration Product Enhancement or idea therefor shall prior
to any such incorporation, notify the other Party thereof. Thereafter, the Party
with Engineering Responsibility for the Cannibalized Product shall have the
right to block the other Party from incorporating the Collaboration Product
Enhancement into the Cannibalizing Product.

         2.4      COLLABORATION PRODUCT ENHANCEMENTS.

                  (a) GENERAL. Collaboration Product Enhancements developed
during the Term and ideas for Collaboration Product Enhancements shall,
subject to Section 2.4(b) hereof, be shared between the parties without any
adjustment to the terms and conditions of this Agreement. The Party with a
Collaboration Product Enhancement or idea therefor will provide it to the
Party with Engineering Responsibility for the Collaboration Product to which
such enhancement or idea applies. Such responsible Party shall decide whether
further development of such Collaboration Product Enhancement or idea
therefor is warranted. The Party with an idea for a Collaboration Product
Enhancement is not obligated to develop it, but is obligated to provide all
information in its possession related thereto to the Party with Engineering
Responsibility for the Collaboration Product to which it applies. Further
development shall be by the Party with Engineering Responsibility therefor,
provided, however, if the Party with Engineering Responsibility wants the
other Party to do further development, the Parties shall negotiate in good
faith regarding reimbursement for the expense of such further development.
No party shall be reimbursed for any development costs incurred relating to
such Collaboration Product Enhancement or idea therefor incurred prior to an
agreement between the Parties regarding reimbursement.

                  (b) THE PAMELA SYSTEM. Within fifteen (15) days of the
Effective Date, Rosetta and Agilent will meet to identify the technology held
by each Party with respect to certain potential enhancements and refinements
that Rosetta has developed and proposes be incorporated into the current
Pamela System (the "Rosetta Proposed Pamela Enhancements"). At least five (5)
days prior to the meeting, Rosetta will inform Agilent in writing of the
technology fields to be discussed. At such meeting Rosetta will deliver to
Agilent a written description of the Rosetta Proposed Pamela Enhancements,
and Agilent will deliver to Rosetta a written description of any products,
product features, enhancements or refinements that it has developed for
incorporation into the Pamela System (the "Agilent Proposed Pamela
Developments"). On or prior to the ninetieth (90) day following the Effective
Date, Agilent shall notify Rosetta in writing whether the Rosetta Proposed
Pamela Enhancements, taken together, will or will not be licensed by Agilent.
In the event Agilent shall elect to license such Rosetta Proposed Pamela
Enhancements, Agilent shall be required to pay Rosetta, in accordance with
Section 7.7 hereof, a royalty equal to [***] of the Net Revenues associated
with the Royalty Bearing Portion of the Pamela System. In the event Agilent
shall elect not to license such Rosetta Proposed Pamela Enhancements, Rosetta
shall be free, notwithstanding any term or condition herein to the contrary
(including, without limitation, 2.1(d)), to enter into an

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -14-
<PAGE>

arrangement with a Third Party or Third Parties with respect to the design,
development, manufacture, commercialization or use of any or all of such Rosetta
Proposed Pamela Enhancements or any enhancements or refinements thereto and,
notwithstanding any term or condition herein to the contrary, Agilent shall have
no rights of any kind with respect to, nor shall it use, any of such Rosetta
Proposed Pamela Enhancements or any enhancements or refinements thereto,
provided, however, the foregoing shall not restrict the use by Agilent in the
Pamela System or otherwise of the Agilent Proposed Pamela Developments or any
enhancements or refinements thereto.

         2.5 NON-COLLABORATION PRODUCTS. Subject to Section 2.3 and Section
2.7(b) (in the case of Rosetta) and 2.6(b) (in the case of Agilent), each Party
is free to design, develop, manufacture, commercialize and use its
Non-Collaboration Products as it desires without the interference or consent of
the other Party, and such other Party will not be required in any manner to
provide support or service for any such Non-Collaboration Product. Where the
design, development, manufacture or use of any Non-Collaboration Product
requires the use of Agilent Patents in the case of Rosetta, or Rosetta Patents
in the case of Agilent, Rosetta or Agilent, as the case may be, shall agree to a
reasonable royalty arrangement which will allow such Non-Collaboration Product
to be brought to market. The term of any royalty payment obligation shall be as
set forth in Section 2.7(b)(ii) (in the case of payments to Agilent by Rosetta)
and 2.6(b)(ii) (in the case of payments to Rosetta by Agilent). Each Party shall
have the right to exploit Joint Collaboration Inventions outside the
Collaborative Field without accounting to the other.

         2.6      LICENSES TO AGILENT

                  (a)      COLLABORATION PRODUCTS

                           (i) RESOLVER. Subject to the terms and conditions
of this Agreement (including, without limitation, Section 7 hereof), Rosetta
hereby grants to Agilent a worldwide (outside of Korea) license, co-exclusive
with Rosetta, in, to and under the Rosetta Technology to market, distribute,
offer for sale, sell, support and use for internal purposes Resolver in the
Agilent Field; provided, however, that the license in, to and under the '888
Patent granted to Agilent in this Section 2.6(a)(i) shall be solely limited
to a worldwide (outside of Korea), non-exclusive license to use Resolver. No
right is hereby granted to Agilent to use or sublicense the methods claimed
in the '888 Patent other then granted herein. No right is hereby granted to
Agilent to decompile, reverse engineer or prepare derivative works of
Resolver. Rosetta represents that it has not heretofore granted, and during
the Term shall not grant, any other licenses in, to and under the Rosetta
Technology that would grant the licensee the right to market, distribute,
offer for sale, sell or support Resolver except within the Excluded Field or
except outside the Agilent Field. Agilent may, with the prior written consent
of Rosetta, sublicense the distribution rights to Resolver set forth above.
No other license rights granted to Agilent under this subsection 2.6(a)(i)
may be sublicensed or transferred by Agilent. Rosetta will provide source
code and documentation with respect to Resolver to an escrow agent under
terms set forth in Section 6.10 of this Agreement.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -15-
<PAGE>

                           (ii) ARRAYS. Subject to the terms and conditions
of this Agreement (including, without limitation, Section 7 hereof) and the
University of Washington License Agreement, Rosetta hereby grants to Agilent
(A) a worldwide license, co-exclusive with Rosetta in, to and under the
Inkjet Technology and such aspects of the Rosetta Technology that pertain to
the fabrication of Arrays to develop and use Arrays for internal use except
in connection with the fields of Genotyping and Diagnostic Products, (B) a
worldwide exclusive license in, to and under the Inkjet Technology and such
aspects of the Rosetta Technology that pertain to the fabrication of Arrays
to manufacture for sale, market, offer for sale and sell Arrays except in
connection with the fields of Genotyping and Diagnostic Products and (C) a
worldwide non-exclusive license in, to and under the Inkjet Technology and
such aspects of the Rosetta Technology that pertain to the fabrication of
Arrays to develop, manufacture for sale, market, offer for sale and sell
Arrays in the field of Diagnostic Products. Rosetta represents that it has
not heretofore granted, and during the Term shall not grant, any other
licenses in, to and under the Inkjet Technology or such aspects of the
Rosetta Technology that pertain to the fabrication of Arrays that would grant
the licensee the right to develop, manufacture for commercial sale, market,
offer for sale, sell or use Arrays except outside the Agilent Field. Agilent
may sublicense the manufacturing and the distribution rights granted to it
under this subsection 2.6(a)(ii) to any Affiliate or to the entities
indicated on Exhibit H and, with the prior written consent of Rosetta (not to
be unreasonably withheld), to any other Third Party. No other license rights
granted to Agilent pursuant to this Section 2.6(a)(ii) may be sublicensed or
transferred by Agilent.

                           (iii) OLIGO SET DESIGN SERVICES. Subject to the terms
and conditions of this Agreement (including, without limitation, Section 7
hereof), Rosetta hereby grants to Agilent a worldwide (outside of Korea)
license, co-exclusive with Rosetta in, to and under the Oligo Set Design
Technology and such aspects of the Rosetta Technology incorporated into Oligo
Set Design Services and enhancements and refinements thereto that pertain to the
choice and layout of oligonucleotides on Arrays, to develop, market, offer for
sale and sell oligo set design methods and techniques applicable to Oligo Set
Design Services in the Agilent Field. No right under the Rosetta Technology is
hereby granted to Agilent to develop, market, offer for sale and sell oligo set
design methods and techniques applicable to Oligo Set Design Services outside
the Agilent Field. Rosetta represents that it has not heretofore granted, and
during the Term shall not grant, any licenses in, to and under the Oligo Set
Design Technology that would grant the licensee the right to develop, market,
offer for sale or sell oligo set design methods and techniques applicable to
Oligo Set Design Services except outside the Agilent Field. No license rights
granted to Agilent under this subsection 2.6(a)(iii) may be sublicensed or
transferred except with the written consent of Rosetta (not to be unreasonably
withheld).

                           (iv) PAMELA SYSTEM. Subject to the terms and
conditions of this Agreement (including, without limitation, Section 7
hereof), Rosetta hereby grants to Agilent, commencing on the date that
Agilent shall elect to license the Rosetta Proposed Pamela Enhancements
pursuant to and in accordance with Section 2.4(b), a worldwide license,
co-exclusive with Rosetta, in, to and under the Rosetta Technology to
develop, use, manufacture, market, offer for sale, sell and support the
Rosetta Proposed Pamela Enhancements and any enhancements and refinements
thereto with the Pamela System. No right is hereby granted in the Rosetta
Proposed Pamela Enhancements in the event Agilent shall elect not to license
the Rosetta

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -16-
<PAGE>

Proposed Pamela Enhancements under Section 2.4(b). Subject to the terms
and conditions of this Agreement (including, without limitation, Section 7
hereof), Rosetta hereby grants to Agilent a worldwide non-exclusive license in,
to and under the Rosetta Technology (except for the Rosetta Proposed Pamela
Enhancements) to develop, use, manufacture, market, offer for sale, sell and
support the Pamela System (to the extent any Rosetta Technology is incorporated
into the Pamela System) in the Agilent Field. Agilent may sublicense the
manufacturing and distribution rights granted to it under this Section
2.6(a)(iv) except to the extent any Rosetta Technology shall be incorporated
into the Pamela System, in which event Agilent may sublicense such rights to any
Affiliate or to the entities indicated on Exhibit I and, with the prior written
consent of Rosetta (not to be unreasonably withheld), to any other Third Party.

                           (v) NEW PRODUCTS. Subject to the terms and conditions
of this Agreement (including, without limitation, Section 7 hereof), Rosetta
hereby grants to Agilent a worldwide, non-exclusive license in, to and under the
Rosetta Technology to develop Agilent New Products.

                           (vi) EXCLUDED GRANTS. Notwithstanding the license
grants set forth in Sections 2.6(a)(i) through 2.6(a)(v) and Sections 10.3 and
10.4, no license in, to or under the Rosetta Technology is granted to Agilent
with respect to the Excluded Field.

                           (vii) AGREEMENT TO NOTIFY OF PATENT COVERAGE. Rosetta
will notify Agilent in writing at the time Rosetta proposes to incorporate
subject matter claimed in a Rosetta Patent that was first applied for prior to
or during the Term into a Collaboration Product or Collaboration Product
Enhancement, or to practice such a Rosetta Patent in the development or
manufacture of a Collaboration Product or Collaboration Product Enhancement, or
at the time Rosetta learns that such Rosetta Patent covers a Collaboration
Product or Collaboration Product Enhancement.

                  (b)      NON-COLLABORATION PRODUCTS.

                           (i) ROSETTA KNOW-HOW LICENSE. Subject to the terms
and conditions of this Agreement (including, without limitation, Section 7
hereof), Agilent shall have, and Rosetta hereby grants to Agilent, a
worldwide (outside of Korea), non-exclusive license to Rosetta Know-How to
develop, make, have made, use, import, offer for sale, sell and support, in
the Agilent Field, all Agilent Non-Collaboration Products that include
Rosetta Know-How for so long as such Rosetta Know-How incorporated therein is
material to the design, development, manufacture or use of such Agilent
Non-Collaboration Products and Agilent shall, for the duration of such period
(but in no event to exceed the tenth (10th) anniversary of the Expiration
Date or Early Termination Date, as the case may be), pay to Rosetta the
royalty required pursuant to Section 2.5 hereof, provided, however, that no
right is hereby granted to Agilent to reverse engineer, decompile or prepare
derivative works of Resolver. Upon request from Agilent, Rosetta will use
reasonable business efforts to provide to Agilent such Rosetta Know-How or to
allow Agilent access to such Rosetta Know-How in a reasonable format, subject
to Agilent's continued compliance with Article 9 hereof.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -17-
<PAGE>

                           (ii) ROSETTA PATENT LICENSE. Subject to the terms and
conditions of this Agreement (including, without limitation, Section 7 hereof),
Agilent shall have, and Rosetta hereby grants Agilent, a worldwide (outside of
Korea), non-exclusive license to develop, make, have made, use, import, offer
for sale, sell and support in the Agilent Field, Agilent Non-Collaboration
Products that include Invention(s) covered by Rosetta Patents for the duration
of the term of any valid patent within the Rosetta Patents covering such Agilent
Non-Collaboration Product, and Agilent shall, for the duration of such period,
pay to Rosetta the royalty required pursuant to Section 2.5 hereof.

                  (c) RETAINED RIGHTS. All rights in Rosetta Technology not
expressly granted to Agilent in this Agreement are retained exclusively by
Rosetta.

         2.7      LICENSES TO ROSETTA

                  (a)      COLLABORATION PRODUCTS.

                           (i) RESOLVER. Subject to the terms and conditions of
this Agreement (including, without limitation, Section 7 hereof), Agilent hereby
grants to Rosetta a worldwide license, co-exclusive with Agilent, in, to and
under the Agilent Technology to develop, use, manufacture, market, distribute,
offer for sale, sell, reproduce, prepare derivative works of Resolver, display
and perform publicly, and support Resolver (to the extent any Agilent Technology
is incorporated into Resolver) provided that no right under the Agilent
Technology is granted to Rosetta to develop, use, manufacture, market,
distribute, offer for sale, sell, reproduce, prepare derivative works, display
and perform publicly, and support Resolver (to the extent any Agilent Technology
is incorporated into Resolver) in connection with [***]. Rosetta
may sublicense the manufacturing rights granted to it under this Section
2.7(a)(i) except to the extent any Agilent Technology shall be incorporated into
Resolver, in which event Rosetta may sublicense such rights only with the prior
written consent of Agilent (such consent not to be unreasonably withheld).

                           (ii) ARRAYS. Subject to the terms and conditions of
this Agreement (including, without limitation, Section 7 hereof), Agilent hereby
grants to Rosetta a worldwide license, co-exclusive with Agilent, in, to and
under Agilent Technology, to design, develop, use, support, and manufacture
Arrays for internal use only (internal use includes, without limitation, the
right to use Arrays in providing commercial services to Third Parties). Agilent
represents that it has not heretofore granted, and during the Term shall not
grant, any licenses in, to and under the Agilent Technology that would grant the
licensee the right to design, develop, manufacture, sell or use Arrays.

                           (iii) OLIGO SET DESIGN SERVICES. Subject to the terms
and conditions of this Agreement (including, without limitation, Section 7
hereof), Agilent hereby grants to Rosetta a worldwide license, co-exclusive with
Agilent, in, to and under the Agilent Technology to develop, market, offer for
sale, sell and use oligo set design methods and techniques applicable to Oligo
Set Design Services. No right under the Agilent Technology is hereby granted to
Rosetta to develop, market, offer for sale and sell oligo set design methods and
techniques applicable to Oligo Set Design Services in connection with [***].
Agilent represents that it has

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -18-
<PAGE>

not heretofore granted, and during the Term shall not grant, any licenses under
the Agilent Technology that would grant the licensee the right to develop,
market, offer for sale, sell or use oligo set design methods and techniques
applicable to Oligo Set Design Services. No license rights granted to Rosetta
under this subsection 2.7(a)(iii) may be sublicensed or transferred except with
the written consent of Agilent (not to be unreasonably withheld).

                           (iv) PAMELA SYSTEM. Subject to the terms and
conditions of this Agreement, Agilent hereby grants to Rosetta a royalty-free
license in, to and under the Agilent Technology to use for internal purposes
(including, without limitation, the right to use the Pamela System in providing
commercial services to Third Parties) only the Pamela Systems delivered to
Rosetta by Agilent pursuant to Section 7.5 hereof except for within the Excluded
Field and except in connection with [***].

                           (v) NEW PRODUCTS. Subject to the terms and conditions
of this Agreement (including, without limitation, Section 7 hereof), Agilent
hereby grants to Rosetta a worldwide, non-exclusive license in, to and under the
Agilent Technology to develop Rosetta New Products.

                           (vi) AGREEMENT TO NOTIFY OF PATENT COVERAGE. Agilent
will notify Rosetta in writing at the time Agilent proposes to incorporate
subject matter claimed in an Agilent Patent that was first applied for prior to
or during the Term into a Collaboration Product or Collaboration Product
Enhancement, or to practice such an Agilent Patent in the development or
manufacture of such a Collaboration Product or Collaboration Product
Enhancement, or at the time Agilent learns that such an Agilent Patent covers
such a Collaboration Product or Collaboration Product Enhancement.

                  (b)      NON-COLLABORATION PRODUCTS.

                           (i) AGILENT KNOW-HOW LICENSE. Subject to the terms
and conditions of this Agreement (including, without limitation, Section 7
hereof), Rosetta shall have, and Agilent hereby grants to Rosetta, a
worldwide, non-exclusive license to develop, make, have made, use, import,
offer for sale, sell and support for Gene Expression purposes only, all
Rosetta Non-Collaboration Products that include Agilent Know-How for so long
as such Agilent Know-How incorporated therein is material to the design,
development, manufacture or use of such Rosetta Non-Collaboration Products
and Rosetta shall, for the duration of such period (but in no event to exceed
the tenth (10th) anniversary of the Expiration Date or Early Termination
Date, as the case may be) pay to Agilent the royalty required pursuant to
Section 2.5 hereof. Upon request from Rosetta, Agilent will use reasonable
business efforts to provide to Rosetta such Agilent Know-How or to allow
Rosetta access to such Agilent Know-How in a reasonable format, subject to
Rosetta's continued compliance with Article 9 hereof.

                           (ii) AGILENT PATENT LICENSE. Subject to the terms and
conditions of this Agreement (including, without limitation, Section 7 hereof),
Agilent hereby grants Rosetta a worldwide, non-exclusive license to develop,
make, have made, use, import, offer for sale, sell and support for Gene
Expression purposes only, Rosetta Non-Collaboration Products that include
Invention(s) covered by Agilent Patents for the duration of the term of any
valid patent within the

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -19-
<PAGE>

Agilent Patents covering such Rosetta Non-Collaboration Product, and Rosetta
shall, for the duration of such period, pay to Agilent the royalty required
pursuant to Section 2.5 hereof.

                  (c) RETAINED RIGHTS. All rights in Agilent Technology not
expressly granted to Rosetta in this Agreement are retained exclusively by
Agilent.

         2.8 FUTURE THIRD PARTY LICENSES. After the Effective Date, if either
Agilent or Rosetta believes that additional intellectual property or technology
controlled by a Third Party ("Third Party Technology") is required or desirable
in order to proceed without interference in the design, development,
manufacture, commercialization or use of one or more Collaboration Products and
the consideration required to acquire rights with respect to such Third Party
Technology would in the reasonable estimation of either Party materially deprive
such Party of the benefit of its bargain hereunder, then the Parties will
collectively determine whether to seek a license to such Third Party Technology,
and if so, on what terms.

         2.9 OLIGO SET DESIGN FUNCTIONALITY. No later than thirty (30) days
after the Effective Date, Rosetta and Agilent will meet to identify the
technology held by each Party with respect to oligo set design methods and
techniques. On or prior to sixty (60) days following the Effective Date, Agilent
and Rosetta shall, based on the technology previously disclosed and market
considerations, determine the oligo set design functionality that will initially
be included in the Pamela-Resident Set Design Software and in the Oligo Set
Design Services offered hereunder. The Parties shall decide, in good faith,
whether such determination shall merit an adjustment to the revenue sharing or
royalty arrangements hereunder.

3.       COLLABORATION MANAGEMENT

         3.1 COLLABORATION PLANNING. Implementation of the design,
development, manufacture and commercialization of the Collaboration Products
will be guided by Hewlett-Packard's Ten-Step Business Planning and Review
Process as documented in various Hewlett-Packard publications which have been
made available to Rosetta prior to the Effective Date (Ref: Booklet "Ten-Step
Business Planning Fundamentals" Hewlett-Packard Corporate Education Oct.
1997. The planning and review process will include preparation of a written
business plan (the "Business Plan") which will provide, among other things,
an assessment of customer needs and the competitive situation in the
Collaboration Products' markets, a detailed 15-month Product Development
Roadmap including a 5-Year Product Development Vision, Marketing/Distribution
and Support, and Manufacturing Plans Covering such periods and other elements
as deemed necessary by the Parties. The Parties will use reasonable business
efforts to complete the initial Business Plan by the end of the third month
following the Effective Date. The Business Plan will be reviewed by the
Parties at least on an annual basis, with any revisions thereto being due at
the end of June of each year during the Term. The process will be managed by
the Collaboration Managers of both Parties, who shall designate Business
Planning Teams representing the functional areas of Marketing/Sales/Support,
Research and Development, Manufacturing and Finance.

         3.2 COLLABORATION MANAGEMENT. The purpose of the collaboration
management structure set forth below is to coordinate and expedite the design,
development, manufacture,

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -20-
<PAGE>

commercialization and use of Collaboration Products. Each Party shall assign
individuals from within their respective organizations to each of the following
positions. Each Party may, in its sole discretion, replace the assigned
individuals at any time as necessary.

                  (a)      EXECUTIVE SPONSORS.

                           (i) APPOINTMENT; MEETINGS. Within ten (10) days of
the Effective Date, each Party shall appoint one (1) individual to be its
executive sponsor ("Executive Sponsor") for the collaboration under this
Agreement. Each Party's Executive Sponsor shall be a senior executive of such
Party with the authority to make binding commitments on behalf of such Party
with respect to its rights and responsibilities hereunder.

                           (ii) RESPONSIBILITIES. The Executive Sponsors shall
have the following specific responsibilities:

                                    (1) approving the Business Plan, by
execution thereof in writing;

                                    (2) settling disputes or disagreements that
cannot be resolved by the Collaboration Managers; and

                                    (3) performing such other functions as
appropriate to further the purposes of this Agreement as determined by the
Parties.

                           (iii) DECISION-MAKING. The Executive Sponsors shall
make decisions by unanimous vote. Whenever the Executive Sponsors are unable to
reach a consensus on a particular issue, such issue shall be discussed not less
than twice during consecutive meetings in order to ensure that all aspects and
concerns of both Parties are thoroughly reviewed and considered. If after such
discussions, the Executive Sponsors are still not able to reach a consensus on
such issue, the Parties shall be required to undertake the dispute resolution
procedures set forth in Article 12 hereof.

                  (b)      COLLABORATION MANAGERS.

                           (i) APPOINTMENT; MEETINGS. Within ten (10) days of
the Effective Date, each Party shall appoint one (1) individual to be its
Collaboration Manager. The Collaboration Managers shall meet not less than
monthly during the Term, unless otherwise mutually agreed by the Parties.
Meetings of the Collaboration Managers will be held alternately at the
facilities of the Parties in Palo Alto, California, or Kirkland, Washington, or
by teleconference. Each Party's employees and agents involved in the
collaboration set forth herein shall, prior to such meeting, report to the
Collaboration Managers on all relevant issues relating to the design,
development, manufacture, commercialization and use of the Collaboration
Products. Minutes of the meetings of the Collaboration Managers shall be
prepared alternately by the Parties and such minutes shall promptly thereafter
be provided to the Executive Sponsors for review.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -21-
<PAGE>

                           (ii) RESPONSIBILITIES. The Collaboration Managers
shall have general responsibility for preparation of the Business Plan and the
design, development, manufacture, commercialization and use of Collaboration
Products as expeditiously as practicable. The initial Business Plan shall be
completed by the Collaboration Managers within ninety (90) days of the Effective
Date. The Collaboration Managers shall also have the following specific
responsibilities:

                                    (1) directing the process of preparing the
product plan (each, a "Product Plan") for each Collaboration Product.

                                    (2) updating and revising the Business Plan
annually or as mutually agreed;

                                    (3) monitoring and reviewing the progress of
research, development, manufacturing, marketing, distribution and finance
activities in order to ensure that satisfactory progress is being made with
respect to the execution of the Business Plan and Product Plans;

                                    (4) discussing and agreeing upon remedial
measures if a Collaboration Manager determines that the progress in respect of
implementation of a Product Plan is unsatisfactory;

                                    (5) settling disputes or disagreements that
cannot be resolved by the Product Managers;

                                    (6) performing such other functions as

appropriate to further the purposes of this Agreement as determined by the
Parties.

                           (iii) DECISION-MAKING. Decisions of the Collaboration
Managers shall be made by unanimous vote. If the Collaboration Managers become
deadlocked on an issue, the issue shall be presented to the Executive Sponsors
for resolution.

                  (c) PRODUCT MANAGERS. Each Party shall appoint one of its
employees as a Product Manager for each Collaboration Product. Such Product
Manager will be responsible for overseeing the day-to-day operations of such
Party with respect to the Collaboration Product for which he or she is
responsible, and for facilitating the achievement of agreed development
milestones for such Collaboration Product. A Product Manager may be responsible
for more than one Collaboration Product.

                  (d) PROJECT TEAMS. Wherever practical, the Collaboration
Managers may, after consulting with an employee's immediate supervisor, consider
teaming employees from one Party to assist the other in areas where those
employees have relevant experience, provided that any disagreements regarding
staffing with respect to any Collaboration Product that cannot be resolved
between the Collaboration Managers will be resolved by the Party to whom
Engineering Responsibility is assigned in Sections 4.2(a) and 4.2(b).

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -22-
<PAGE>

4.       COLLABORATION DEVELOPMENT

         4.1 SCOPE. The Parties agree to use the CAG Project Lifecycle
(Revision of October 1997 and future revisions) as the guide for establishing
a detailed Product Plan for each Collaboration Product. Each Product Plan
will contain, among other things, a Development Plan, a
Marketing/Sales/Support Plan and a Manufacturing Plan, and will provide
processes for the implementation and review of such plans in a consistent and
logical framework. A copy of the CAG Project Lifecycle has been provided to
Rosetta prior to the Effective Date.

         4.2      ALLOCATION OF ENGINEERING RESPONSIBILITIES.

                  (a) ROSETTA RESPONSIBILITIES. Rosetta will have Engineering
Responsibility for Resolver and Oligo Set Design Services, and integration of
each thereof into other Collaboration Products. Solely for purposes of Section
2.2(b) hereof, Rosetta will also have Engineering Responsibility for any
software (other than Feature Extraction Software) for Gene Expression profiling.

                  (b) AGILENT RESPONSIBILITIES. Agilent will have Engineering
Responsibility for the Pamela System, Arrays, Array manufacturing and overall
system integration of Collaboration Products, subject to Rosetta's Engineering
Responsibility as described in Section 4.2(a) hereof. Agilent will make
recommendations for each element of a Collaboration Product regarding the
performance characteristics thereof to ensure that all elements function as a
complete system when assembled. Agilent shall offer to Rosetta a first right of
negotiation for an exclusive arrangement with Agilent regarding any design,
development, and manufacture of software (other than Feature Extraction
Software) proposed by Agilent for Gene Expression profiling in connection with
[***].

                  (c) ALLOCATION OF FURTHER RESPONSIBILITIES IN THE DEVELOPMENT
PLANS. If Engineering Responsibility for a Collaboration Product is not
specified by Sections 4.2(a) and 4.2(b) above, such responsibility will be
specified in the Development Plan therefor as amended from time to time. The
Collaboration Managers may mutually agree to assign Engineering Responsibility
differently than provided in Sections 4.2(a) and 4.2(b) above on a case-by-case
basis.

         4.3 DUE DILIGENCE. Each Party shall use diligent and reasonable
business efforts to carry out development of each Collaboration Product in
accordance with the mutually agreed Product Plans.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -23-
<PAGE>

5.       MANUFACTURING

         5.1      MANUFACTURING RESPONSIBILITIES

                  (a) MANUFACTURE BY ROSETTA. Rosetta shall be responsible for
the manufacture and supply of Resolver and the supply of the Resolver Platform.
Rosetta may, subject to Section 2.7(a)(i) hereof, engage Third Parties to
manufacture Resolver and supply the Resolver Platform, provided that Rosetta
retains ultimate responsibility for the final product.

                  (b) MANUFACTURE BY AGILENT. Agilent shall be responsible for
the manufacture and supply of Arrays and the Pamela System. Agilent may, subject
to Section 2.6(a)(iv) hereof, engage Third Parties to manufacture and supply
Arrays, Components of Arrays or the Pamela System, provided that Agilent retains
ultimate responsibility for the final product. Agilent may engage Rosetta to
manufacture Arrays under terms to be agreed between the Parties.

         5.2      PRODUCTION PLANNING

                  (a) ESTABLISHMENT OF MANUFACTURING CAPACITY. The Manufacturing
Plan shall be designed to ensure sufficient supply of all Collaboration Products
to satisfy market demand.

                  (b) In the event the Parties determine it desirable to share
Array manufacturing responsibilities, the Parties shall enter into a
manufacturing arrangement wherein Agilent shall grant Rosetta the necessary
rights to make Arrays for Agilent on a mutually agreeable basis.

         5.3 DUE DILIGENCE. Each Party shall use diligent and reasonable
business efforts in manufacturing the Collaboration Products for which such
Party has manufacturing responsibility.

6.       MARKETING, SALES AND SUPPORT OF COLLABORATION PRODUCTS

         6.1 AGILENT RESPONSIBILITIES. Agilent shall have the responsibility and
exclusive right to sell, distribute and support Arrays and the Pamela System.
All such activities shall be conducted in accordance with the terms of this
Agreement and the Product Plan for such Collaboration Products jointly developed
and agreed by the Parties as provided in Article 3. Agilent's activities
pursuant to this Section 6.1 shall be at its own expense.

         6.2 ROSETTA RESPONSIBILITIES. Rosetta shall have the responsibility and
exclusive right to manufacture Resolver and to provide documentation and
marketing literature therefor. Rosetta shall also have the responsibility to
ship Resolver and provide support therefor. All such activities shall be
conducted in accordance with the terms of this Agreement and the Product Plan
for Resolver jointly developed and agreed by the Parties as provided in Article
3. Rosetta's activities pursuant to this Section 6.2 shall be at its own
expense.

         6.3 SHARED RESPONSIBILITIES. Agilent and Rosetta will share
responsibility for selling Resolver (including maintenance and support
contracts) and Oligo Set Design Services for TAP

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -24-
<PAGE>

Sales and Commercial Sales, provided that the Parties hereby acknowledge and
agree that Agilent will manage the customer interface and sales process for both
TAP Sales and Commercial Sales.

         6.4      BRANDING.

                  (a) Rosetta will mark Resolver with appropriate "Rosetta" and
"Resolver" trademarks. Subject to Agilent's internal trademark clearance
procedures and corporate identity standards related to co-branding, Rosetta will
during the Term also mark Resolver, or permit Agilent to mark Resolver, with the
Agilent company and product trademarks as a prominent sub-brand.

                  (b) Subject to Agilent's internal trademark clearance
procedures and corporate identity standards relating to co-branding, Agilent
will mark, or allow Rosetta to mark, all IN SITU Arrays, all Oligo Deposited
Arrays designed with the use of Rosetta's Oligo Set Design Services and all
other Arrays incorporating any Rosetta Technology with appropriate "Rosetta"
trademarks as a prominent sub-brand.

         6.5 DISTRIBUTORS. Subject to the terms and conditions of this
Agreement, Agilent will have the right to use Affiliates and the Third Parties
indicated on Exhibit J to distribute Resolver and to distribute and support
other Collaboration Products around the world. Agilent may also use Third
Parties not indicated on Exhibit J to distribute Resolver and to distribute and
support other Collaboration Products around the world with the prior written
consent of Rosetta (not to be unreasonably withheld).

         6.6 PACKAGING AND LABELING. The Collaboration Products shall be
packaged and labeled consistent with the requirements of the applicable laws of
the countries where a Collaboration Product is sold.

                  (a) The Parties agree to discuss patent marking on a
case-by-case basis prior to product introduction in accordance with the Parties'
internal guidelines on patent marking to preserve patent rights and rights to
damages in the event of infringement. If applicable, such patent marking shall
identify Agilent and Rosetta as the manufacturers of such Collaboration Product.

                  (b) The Parties agree to label Collaboration Products
consistent with the requirements of licenses granted by Third Party licensors if
applicable.

         6.7 ADVERTISING, PROMOTIONAL AND EDUCATIONAL MATERIALS. The Parties
shall in the Business Plan establish guidelines for the use of Agilent's and
Rosetta's corporate names, logos and trademarks in written sales, promotional,
educational and advertising materials relating to Collaboration Products. All
such written and visual materials and all documentary information and
promotional materials will portray Agilent, Rosetta and their respective
corporate names, logos and trademarks in a manner consistent with their
respective internal guidelines with respect thereto.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -25-
<PAGE>

         6.8 CUSTOMER SUPPORT. Agilent shall manage the customer interface and
support process and shall provide a first level of support for all Collaboration
Products. Rosetta will use reasonable business efforts to provide backup
technical support to Agilent for any Collaboration Products using Rosetta
Technology to the extent such technical support involves the incorporated
Rosetta Technology. Rosetta shall provide support for Resolver and Oligo Set
Design. Agilent will use reasonable business efforts to provide backup
non-technical assistance to Rosetta in this endeavor with the understanding that
Agilent is not obligated to provide any dedicated technical staffing for such
efforts. The Collaboration Managers will agree on a mechanism by which Rosetta
and Agilent will obtain direct end-user customer feedback regarding
Collaboration Products.

         6.9 DUE DILIGENCE. Each Party shall use reasonable business efforts in
marketing, promoting, selling and supporting the Collaboration Products
according to its responsibilities as set out in this Agreement.

         6.10 SOFTWARE ESCROW. Upon the request of Agilent, Rosetta shall,
pursuant to the Source Code Escrow Agreement attached as Exhibit K, place in
escrow the source code of Resolver, the source code of any software product used
in Oligo Set Design Services, and any other software product developed by
Rosetta which is incorporated into, or becomes, a Collaboration Product. Should
Agilent develop any software to be incorporated into Resolver, Agilent shall
provide to Rosetta the source code and documentation related to such software.

7.       FINANCIAL AND COMMERCIAL TERMS

         7.1 EQUITY INVESTMENT. On the Effective Date, the Parties shall
execute, deliver and perform (to the extent applicable) the Stock Purchase
Agreement and Related Financing Documents.

         7.2 RESEARCH AND DEVELOPMENT FUNDING.

                  (a) FUNDING SCHEDULE. Agilent shall make $6,200,000 in
research and development payments to Rosetta under this Agreement during the
initial [***] of the Term as follows:

                  Agilent shall pay Rosetta [***] on the Effective Date,
[***] on [***].

                  (b) ROSETTA RESEARCH AND DEVELOPMENT. Rosetta's research and
development activities funded with amounts paid by Agilent pursuant to Section
7.2(a) shall initially focus on continuing development of Resolver, Oligo Set
Design Services, Array design and Array manufacturing technologies. The research
and development funding provided Rosetta hereunder is intended to support these
efforts consistent with the agreed Business Plan.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -26-
<PAGE>

         7.3 LICENSE MAINTENANCE FEE. On the Effective Date, Agilent shall pay
Rosetta [***] in consideration for the exclusive right to collaborate with
Rosetta in respect of the Collaboration Products, and to maintain during the
Term, subject to the terms and conditions of this Agreement, exclusive or
co-exclusive, as the case may be, license rights in respect of Rosetta
Technology used in the Collaboration Products pursuant to Section 2 hereof.

         7.4      REVENUE SHARING/ ROYALTIES

                  (a) REVENUE SHARING COLLABORATION PRODUCTS. During the
Term, Agilent and Rosetta will allocate Shared Commercial Revenues, Shared
TAP Revenues and Shared Design Revenues as provided in Exhibit L, provided,
however, the Parties understand and agree that revenues from the sale or
other disposition in TAP Sales and Commercial Sales by Rosetta or Agilent, as
the case may be, of the Resolver Platform and maintenance and support
contracts for the Resolver Platform shall not be allocated between the
Parties, but that Agilent shall pay to Rosetta (and Rosetta shall be entitled
to retain) all such revenues in their entirety, provided, further, the
parties understand and agree that as of the Effective Date Rosetta is
negotiating agreements in respect of the sale or other disposition of
Resolver to DuPont Pharmaceuticals, Inc., [***], and in the event a sale or
other disposition of Resolver results therefrom within ninety (90) days after
the Effective Date, all Net Revenues associated therewith will not be
allocated between the Parties but will be Rosetta's exclusively.

                  (b) ROYALTY-BEARING COLLABORATION PRODUCTS. During the Term
and thereafter as provided in Section 10.3 or 10.4, as the case may be, Agilent
will pay royalties to Rosetta on Net Revenues of the Collaboration Products as
provided in Exhibit L.

         7.5      PROVISION OF PAMELA SYSTEM AND RESOLVER.

                  (a) PAMELA SYSTEM. Within ninety (90) days of the Effective
Date, Agilent shall deliver to Rosetta [***] for use by Rosetta during the
Term for internal purposes only. The Parties shall agree on a delivery
schedule for additional Pamela Systems based on production schedules and
customer demand. Rosetta shall reimburse Agilent for the manufacturing costs
incurred by it in connection with each such Pamela System, provided, however,
in no event shall such manufacturing costs for each such Pamela System exceed
[***].

                  (b) RESOLVER. As soon as practicable after the Effective
Date, Rosetta shall deliver to Agilent [***] and the applicable Resolver
Platform for use by Agilent during the Term for internal purposes. Agilent
shall, in consideration for such Resolver, reimburse Rosetta for the costs
[***] incurred by Rosetta in connection with acquiring and configuring
Resolver and the Resolver Platform, including costs associated with
installation, documentation, training and support.

         7.6 BUNDLING AND PRICING. Agilent will, subject to the next following
sentence, establish prices for Collaboration Products exclusively offered by
Agilent that reflect in good faith the fair market value of each such
Collaboration Product. Rosetta will establish the prices

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -27-
<PAGE>

for the Resolver Platform and maintenance and support contracts for the Resolver
Platform and will otherwise assist Agilent in establishing prices for Resolver
configurations and Oligo Set Design Services based on similar fair market value
considerations. The Parties further understand and agree that certain
Collaboration Products may be sold together as a kit or separately, as customers
may require from time to time. In the event Collaboration Products bearing
different royalty rates and non-royalty bearing Collaboration Products are sold
together as a package, royalties shall be calculated based on that portion of
the total purchase price reasonably determined by the Parties to be allocable to
such royalty-bearing Collaboration Products taking into consideration the
purchase price therefor when sold separately.

         7.7 PAYMENTS AND REPORTS. Agilent shall make written reports
(consistent with GAAP or such other policies and practices as required by the
AFM) and royalty and revenue sharing payments (including payment of all amounts
related to the sale or other disposition in TAP Sales or Commercial Sales of the
Resolver Platform and maintenance and support contracts for the Resolver
Platform as provided in Section 7.4(a) hereof) to Rosetta within thirty (30)
days after the close of each Agilent fiscal quarter during the Term. Such
reports shall show for such fiscal quarter sales by Agilent, its Affiliates and
sublicensees, if any, of Collaboration Products, details of the quantities of
each Collaboration Product sold (including type and quantity of each category of
Array), Net Revenues from sales of Collaboration Products on a
product-by-product basis, trade discounts allowed and taken, and the revenue
sharing and royalty amounts due to Rosetta thereon pursuant hereto. In the event
Rosetta shall have sold any Collaboration Product or received any revenue in
connection with a sale of a Collaboration Product (other than pursuant to the
immediately preceding sentence), Rosetta shall likewise deliver to Agilent a
written report (consistent with GAAP) within thirty days (30) days after the
close of each Rosetta fiscal quarter during which any such Collaboration Product
was sold or revenue received by Rosetta and pay over to Agilent, concurrent with
the delivery of such report, any amounts received by Rosetta in connection with
such sale or which were otherwise received, net of the royalty or revenue
sharing amounts otherwise due Rosetta in connection therewith.

         7.8      ACCOUNTING AND AUDIT

                  (a) Agilent will follow Agilent's standard financial
practices, processes and procedures as listed in the AFM. Rosetta will follow
GAAP and will make reasonable efforts in respect of the preparation and delivery
of reports required to be delivered to Agilent pursuant to Section 7.7 to follow
Agilent's standard financial practices, processes and procedures as detailed in
the AFM.

                  (b) Each Party may audit the financial records of the other
Party for the limited purpose of ensuring compliance with the financial
obligations of such other Party under this Agreement. Such an audit may be
conducted not more often than annually, during regular business hours, and on
reasonable advance notice. Such audit will be conducted by an independent
auditor which will be obligated to keep strictly confidential the audited
Party's financial records and other information. The auditor will disclose such
information to the auditing Party only to the extent necessary to establish
compliance or non-compliance with the audited Party's financial obligations and,
if the latter, the magnitude of any discrepancy. The

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -28-
<PAGE>

auditing Party will pay the costs of such audit unless the audit shows that
the audited Party is more than [***] delinquent in its obligations for the
period of the audit as of the end of such period, in which case the audited
Party will pay the costs of the audit.

         7.9      SUPPLY OF ARRAYS TO ROSETTA

                  For so long as Agilent shall offer for sale or sell Arrays,
Agilent shall, in consideration for the licenses granted by Rosetta to
Agilent pursuant to Articles 2 and 10 herein, sell and deliver Arrays to
Rosetta upon Rosetta's request (and in accordance with Rosetta's reasonable
specifications) for use by Rosetta at Rosetta's facilities. Agilent's
standard terms of sale offered to other customers that purchase Arrays shall
apply to sales to Rosetta (including any disclaimer of infringement of Third
Party intellectual property rights), except that the price charged to Rosetta
for such Arrays shall be the greater of (i) [***] or (ii) [***] , provided,
however, [***], and Agilent shall [***]. The Arrays will be delivered on dates
that are reasonable and mutually agreed, and Rosetta will, during the Term,
provide Agilent every [***] a forecast of the number of Arrays it reasonably
expects to purchase during the next following [***]. All such forecasts will
be for the sole purpose of assisting Agilent in its product planning and will
not constitute an obligation of Rosetta to purchase the quantities indicated.
Agilent will invoice Rosetta for all Arrays purchased pursuant to this Section
7.9 promptly upon delivery of such Arrays to Rosetta. In no event will Agilent
set off amounts owing to it by Rosetta under this Section 7.9 against amounts
otherwise due and payable to Rosetta by Agilent hereunder.

         7.10     ADDITIONAL ITEMS

                  (a) Rosetta agrees to provide Agilent promptly after the
Effective Date [***] in consideration for the payment to Rosetta of [***].

                  (b) Agilent agrees to provide Rosetta, when requested and
available, an Agilent-manufactured [***] in consideration for payment to
Agilent of its cost of fabrication.

                  (c) Rosetta shall obtain the right to sublicense Agilent under
the University of Washington License Agreement.

                  (d) In the event Rosetta (or any agent of Rosetta) shall sell
or otherwise dispose of any Resolver or Oligo Set Design Services to a Third
Party located in [***], all Net Revenues associated with such sale or other
disposition shall be allocated between the Parties in accordance with Section
7.4(a), and thereafter paid to Agilent by Rosetta in accordance with Section 7.7
hereof.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -29-
<PAGE>

                  (e) Notwithstanding Sections 4.3, 5.3 and 6.9 hereof, Agilent
will use at least the same level of effort and diligence as Agilent uses or in
the past has used with respect to its own commercially successful products and
on which Agilent places or has placed a priority, in proceeding with (i) the
development, testing and manufacturing of Collaboration products for which it
has Engineering Responsibility and manufacturing obligations hereunder, (ii)
filing for or seeking regulatory approvals as may be determined in the Business
Plan, and (iii) the subsequent marketing and sales of Collaboration Products.

8.       INTELLECTUAL PROPERTY OWNERSHIP; PROSECUTION AND RISK MANAGEMENT

         8.1      OWNERSHIP OF INVENTIONS.

                  (a) Rosetta Collaboration Inventions and any patents and
patent applications on Rosetta Collaboration Inventions shall be owned by and
assigned to Rosetta. Agilent Collaboration Inventions and any patents and patent
applications on Agilent Collaboration Inventions shall be owned by and assigned
to Agilent. Joint Collaboration Inventions and any patents and patent
applications on Joint Collaboration Inventions will be owned jointly by Rosetta
and Agilent and treated as joint inventions under the United States laws
applicable to joint inventions. No Party will have any duty to account to the
other for profits or revenues generated from the commercialization of Joint
Collaboration Inventions except as otherwise specifically provided in this
Agreement.

                  (b) Rosetta shall disclose to Agilent the complete texts of
all patents and patent applications within the Inkjet Patents, Oligo Set Design
Patents, and Rosetta Patents filed by Rosetta which relate to any Collaboration
Product, Collaboration Product Enhancement or Collaboration Invention, as well
as all information received by it concerning the institution or possible
institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any other official proceeding of which it has
knowledge in any jurisdiction involving any patent licensed to Agilent
hereunder. Rosetta agrees to keep Agilent promptly and fully informed of the
course of patent prosecution or other proceedings in respect of Collaboration
Products, Collaboration Product Enhancement or Collaboration Inventions
including by providing Agilent with copies of substantive communications, search
reports and Third Party observations submitted to or received from patent
offices. Agilent shall hold all information disclosed to it under this Section
8.1(b) as confidential in accordance with Section 9.

                  (d) Agilent shall disclose to Rosetta the complete texts of
all patents and patent applications filed by Agilent by or on behalf of its
Bioscience Products Division which relate to any Collaboration Product,
Collaboration Product Enhancement or Collaboration Invention, as well as all
information received by or on behalf of its Bioscience Products Division
concerning the institution or possible institution of any interference,
opposition, re-examination, reissue, revocation, nullification or any other
official proceeding of which it has knowledge in any jurisdiction involving any
patent licensed to Rosetta hereunder. Agilent agrees to keep Rosetta promptly
and fully informed of the course of patent prosecution or other proceedings in
respect of Collaboration Products, Collaboration Product Enhancement or
Collaboration

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -30-
<PAGE>

Inventions including by providing Rosetta with copies of substantive
communications, search reports and Third Party observations submitted to or
received from patent offices. Rosetta shall hold all information disclosed to it
under this Section 8.1(c) as confidential in accordance with Section 9.

                  (d) If any Joint Collaboration Invention is patentable, the
Parties will mutually agree on whether and how to pursue patent protection of
the invention in the United States and elsewhere.

                  (e) Except as otherwise set forth in this Agreement, Rosetta
and Agilent shall retain their respective unrestricted rights to make, have
made, use and sell all Inventions and discoveries that are owned solely by them.

         8.2 ABANDONED PATENTS. In the event either Rosetta or Agilent (acting
by or through its Bioscience Products Division), as the case may be, intends to
finally abandon any patent or patent application or any claim of a patent or
patent application licensed to the other under this Agreement, it shall notify
the other and such other Party shall have the right at its own expense to assume
responsibility for any such patent or the prosecution of any such claim in a
separate patent application.

         8.3 LITIGATION RISKS. The Parties understand and acknowledge that there
are numerous and conflicting patent claims held by a number of Third Parties
which may or may not cover intellectual property used or useful in connection
with the design, development, manufacture, commercialization or use of
Collaboration Products. The Parties agree to cooperate with each other in
assessing and achieving freedom to practice the technologies which are contained
in the Collaboration Products.

9.       CONFIDENTIALITY

         9.1 CONFIDENTIALITY. Except to the extent expressly authorized by
this Agreement or otherwise agreed in writing by the Party that originally
discloses Confidential Information (the "Disclosing Party"), the Party to
whom such Confidential Information is disclosed (the "Recipient") agrees to
keep the Disclosing Party's Confidential Information strictly confidential
for a period of five (5) years from the Expiration Date or Early Termination
Date. Further, until five (5) years from the Expiration Date or Early
Termination Date, neither Party shall use Confidential Information of the
other except for the limited purpose of performing its obligations or
exercising its rights under this Agreement.

         9.2 EXCEPTIONS. The above obligations of non-disclosure and non-use
shall not apply to information which the Recipient can document:

                  (a) was publicly known or available at the time it was
communicated to the Recipient by the Disclosing Party;

                  (b) became publicly known or available subsequent to the time
it was communicated to the Recipient by the Disclosing Party through no fault of
the Recipient;

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -31-
<PAGE>

                  (c) was in the Recipient's possession free of any obligation
of confidence at the time it was communicated to the Recipient by the Disclosing
Party;

                  (d) was rightfully communicated to the Recipient free of any
obligation of confidence subsequent to the time it was communicated to the
Recipient by the Disclosing Party;

                  (e) was independently developed by employees or agents of the
Recipient who had no knowledge of any Confidential Information communicated to
the Recipient by the Disclosing Party; or

                  (f) is or was required to be disclosed in response to a valid
order by a court or other governmental body, was otherwise required by law, or
was necessary to establish the rights of either Party vis a vis the other under
this Agreement.

         9.3      AUTHORIZED DISCLOSURES

                  (a) Notwithstanding Sections 9.1 and 9.2 above, the Parties
hereby acknowledge each other's right to disclose Confidential Information to
Third Parties with whom they have entered into agreements for the purpose of
designing, developing, manufacturing, commercializing or using Collaboration
Products pursuant to and in accordance with the terms and conditions of this
Agreement. If either Party desires to disclose any of the other's Confidential
Information for the purposes set forth in the preceding sentence, prior to any
such disclosure the Parties shall meet to review such planned disclosure and
shall mutually agree on (i) the Confidential Information, if any, to be so
disclosed and (ii) the terms of any such disclosure, which shall include, at a
minimum, confidentiality obligations at least as stringent as those in this
Article 9.

                  (b) Each Party may disclose Confidential Information of the
other Party to the extent such disclosure is reasonably necessary to (i) comply
with applicable securities laws and regulations and other applicable
governmental regulations, (ii) file or prosecute patents relating to Joint
Collaboration Inventions and Collaboration Inventions and (iii) prosecute or
defend litigation relating to Collaboration Products. Notwithstanding the
foregoing, in the event a Party is required to make a disclosure of Confidential
Information as provided in this Section 9.3(b), it will give reasonable advance
notice to the other Party of such disclosure and use reasonable business efforts
to maintain the information as confidential or to secure confidential treatment
of such information. In any event, the Parties agree to take all reasonable
action to avoid disclosure of Confidential Information.

         9.4      COMMUNICATION AND PUBLICITY

                  (a) Either prior to or promptly after the Effective Date, the
Parties shall, together with their respective counsel, meet to discuss a
strategy for public announcement of the collaboration under this Agreement in a
mutually agreed press release issued simultaneously by both Parties. Subject to
the further provisions of this Section 9.4, no Party shall originate any
subsequent written publicity, news release, or other announcement relating to
this Agreement or to performance hereunder or the existence of an arrangement
between the Parties or any

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -32-
<PAGE>

Collaboration Product (collectively, "Written Disclosure"), without the prior
prompt review and written approval of the other. Once specific information has
been approved for disclosure, that information may be repeated in any subsequent
Written Disclosure without further approval.

                  (b) Notwithstanding the foregoing provisions of this Article
9, any Party may make any public Written Disclosure it believes in good faith
based upon the advice of counsel is required by applicable law or any listing or
trading agreement concerning its publicly traded securities, provided that prior
to making such Written Disclosure, the Disclosing Party shall provide the other
Party with a copy of the materials proposed to be disclosed and provide such
Party with a meaningful opportunity to review and comment on the proposed
Written Disclosure.

                  (c) The terms of this Agreement may be disclosed to Third
Parties so long as such disclosure is made pursuant to an agreement of
confidentiality and so long as material financial terms are not disclosed.

10.      TERM AND TERMINATION

         10.1     TERM.

                  The term ("Term") of the Agreement will commence on the
Effective Date and will expire on the earliest to occur of the date (the
"Expiration Date") which is (i) the seventh (7th) anniversary of the
Effective Date (ii) the date on which the design, development, manufacture,
commercialization or use of any Collaboration Product shall be permanently
enjoined pursuant to a Final Order, or (iii) the date on which it shall be
determined, after the Parties have exhausted the rights granted pursuant to
Article 12 hereof (other than a judicial determination), that Agilent shall
not have satisfied its obligations under Section 7.10(e) hereof, unless
earlier terminated pursuant to Section 10.2 hereof. Three hundred sixty-five
(365) days prior to the scheduled Expiration Date, the Parties shall begin
negotiations on an agreement to extend the Term for an additional one to
three (1-3) year period on reasonable terms and conditions (and, in the event
of such an agreement, the Expiration Date shall thereafter be the date to
which the Term shall be so extended). On the Expiration Date, in the absence
of a written agreement to the contrary and to the extent not otherwise
prohibited or enjoined by a Final Order, the Parties shall be bound by
Section 10.3 hereof.

         10.2     EARLY TERMINATION.

                  A Party shall be entitled to terminate this Agreement prior
to the Expiration Date on any date (the "Early Termination Date") with
fifteen (15) days prior written notice specifying such Early Termination Date
in the event, but only in the event, that (i) in material breach of the
exclusive or co-exclusive licensing or business relationships set forth in
this Agreement, the other Party shall have entered, directly or indirectly,
into any agreement, understanding or arrangement (or commitment with respect
thereto) with a Third Party regarding the design, development, manufacture,
commercialization or use (except with respect to the use by an end-user) of a
Collaboration Product, (ii) the other Party shall breach its obligations of
confidentiality contained in Article 9 hereof and, as a result thereof, such
Party shall have sustained material irreparable harm to its competitive
position generally or with respect to any Collaboration

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -33-
<PAGE>

Product or other material product or service then offered by such Party or (iii)
a Bankruptcy Event shall have occurred with respect to the other Party.

         10.3     CONSEQUENCES OF EXPIRATION.

         Upon expiration of the Term of this Agreement pursuant to Section 10.1
hereof (except to the extent otherwise agreed in writing by the Parties or
prohibited or enjoined by a Final Order):

                  (a) PAYMENTS. On the Expiration Date, each Party shall pay the
other Party all sums accrued hereunder which are due to such other Party as of
the Expiration Date, including all revenue and royalty sharing amounts due
pursuant to Section 7 hereof.

                  (b) RESOLVER. On the Expiration Date, all rights granted to
Agilent by Rosetta hereunder in respect of Resolver including, without
limitation, Agilent's co-exclusive right in, to and under the Rosetta
Technology (including the '888 Patent) to market, distribute, offer for sale,
sell and support and use for internal purposes Resolver in the Agilent Field,
shall terminate and expire. To the extent any Agilent Technology is
incorporated into the design, development, manufacture or use of Resolver or
any Component thereof as of the Expiration Date, Rosetta shall have, and
Agilent hereby grants to Rosetta, a worldwide, non-exclusive, irrevocable
license in, to and under such Agilent Technology to design, develop, use,
make, have made, market, distribute, offer for sale, sell, reproduce, prepare
derivative works, display and perform publicly and support Resolver or any
Component thereof for the duration of the term of any valid patent within the
Agilent Patents covering Resolver or any Component thereof, and Rosetta
shall, for the duration of such period, pay to Agilent a commercially
reasonable royalty on Net Revenues associated with the Royalty Bearing
Portion of Resolver taking into account the Agilent Technology so
incorporated; such royalty payments to be made at such times and pursuant to
the reports required to be delivered in accordance with Section 7.7 hereof.

                  In addition, Agilent shall have the right to purchase from
Rosetta, and Rosetta shall, for so long as it shall continue to offer for
sale or sell Resolver, sell Resolver to Agilent as a [***] at the lowest of
(i) [***] or (ii) [***].

                  (c) ARRAYS. On the Expiration Date, Rosetta shall retain the
right in, to and under the Agilent Technology to design, develop, use, support
and manufacture Arrays for internal use only (internal use includes, without
limitation, the right to use Arrays in providing commercial services to Third
Parties), and Rosetta shall retain the right to purchase Arrays pursuant to
Section 7.9 hereof. To the extent any Inkjet Technology or aspects of the
Rosetta Technology that pertain to the fabrication of Arrays is incorporated
into the development, manufacture or use of an Array or any Component thereof as
of the Expiration Date, Agilent shall have, and Rosetta hereby grants to
Agilent, a worldwide, non-exclusive, irrevocable license in, to and under such
Inkjet Technology and such aspects of the Rosetta Technology that pertain to the
fabrication of Arrays to manufacture, offer for sale and sell Arrays
including in connection with [***] except in connection with the field of
[***] for the later of (i) the duration of the term of any valid patent
within the licensed Inkjet Technology or

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -34-
<PAGE>

such aspects of the Rosetta Technology that pertain to the fabrication of
Arrays covering the design, manufacture or use of an Array or any Component
thereof or (ii) for so long (but in no event beyond the tenth (10th)
anniversary of the Expiration Date) as any Rosetta Know-How incorporated
therein is material to the design, development, manufacture or use of an
Array or any Component thereof, and Agilent shall, for the duration of such
period, pay Rosetta a commercially reasonable royalty on Net Revenues of such
Arrays taking into account the Rosetta Technology so incorporated (as
evidenced by the royalty rate, if any, in effect as of the Expiration Date);
such royalty payments to be made at such times and pursuant to the reports
required to be delivered in accordance with Section 7.7 hereof.

                  (d) PAMELA SYSTEM. On the Expiration Date, all rights
granted to Rosetta by Agilent hereunder in respect of the Pamela System
(other than the right to use the Pamela System for internal purposes,
including the right to use the Pamela System in providing commercial services
to Third Parties) shall terminate and expire. To the extent any Rosetta
Technology is incorporated into the design, development, manufacture or use
of the Pamela System as of the Expiration Date, Agilent shall have, and
Rosetta hereby grants to Agilent, a worldwide, non-exclusive, irrevocable
license in, to and under Rosetta Technology to develop, use, manufacture,
market, offer for sale, sell and support the Pamela System and any Component
thereof for the later of (i) the duration of the term of any valid patent
within the Rosetta Patents covering the design, manufacture or use of the
Pamela System or any Component thereof or (ii) for so long (but in no event
beyond the tenth (10th) anniversary of the Early Termination Date) as any
Rosetta Know-How incorporated therein is material to the design, development,
manufacture or use of the Pamela System or any Component thereof, and if on
or prior to such date Agilent shall have agreed or otherwise paid to Rosetta
a royalty with respect to Rosetta Technology incorporated into the design,
development, manufacture or use of the Pamela System, Agilent shall, for the
duration of such period, pay Rosetta a commercially reasonable royalty on Net
Revenues associated with the Royalty Bearing Portion of the Pamela System
taking into account the Rosetta Technology so incorporated (as evidenced by
the royalty rate in effect as of the Expiration Date); such royalty payments
to be made at such times and pursuant to the reports required to be delivered
in accordance with Section 7.7 hereof.

                  (e) NON-COLLABORATION PRODUCTS AND NEW PRODUCTS THAT BECOME
COLLABORATION PRODUCTS. The provisions of this Agreement and the arrangements of
the Parties for any royalties or other amounts owed one to the other on the sale
or other disposition of Non-Collaboration Products or New Products that become
Collaboration Products shall remain unchanged (unless otherwise agreed in
writing) due to the expiration of the Term.

                  (f) OLIGO SET DESIGN SERVICES. In the event this Agreement
expires pursuant to 10.1, the Parties shall agree on an allocation of rights
subsequent to the Expiration Date in respect of Oligo Set Design Services. The
Parties agree to allocate such rights in a manner consistent with and to the
extent possible to preserve the relative competitive positions and allocation of
expenses of the Parties after the Expiration Date with respect to such Oligo Set
Design Services.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -35-
<PAGE>

                  (g) ROSETTA OBLIGATIONS REGARDING RESOLVER. Rosetta shall
use commercially reasonable efforts for a period of five (5) years after the
Expiration Date to support and maintain versions of Resolver sold prior to
the Expiration Date to the installed customer base of Pamela System users,
but only for so long as any such customers use the then most current version
of Resolver.

         10.4 CONSEQUENCES OF EARLY TERMINATION. Upon the early termination of
this Agreement pursuant to Section 10.2 (except to the extent otherwise agreed
in writing by the Parties):

                  (a) PAYMENTS. Each Party shall have the right to retain any
sums paid to it by the other as of the Early Termination Date, and each Party
shall on the Early Termination Date pay the other Party all sums accrued
hereunder which are due to such other Party, including all revenue and royalty
sharing amounts due pursuant to Article 7 hereof.

                  (b) RESOLVER. In the event Rosetta shall terminate this
Agreement pursuant to Section 10.2, all rights granted to Agilent by Rosetta
hereunder in respect of Resolver including, without limitation, Agilent's
co-exclusive right in, to and under the Rosetta Technology (including the
'888 Patent) to market, distribute, offer for sale, sell, support and use for
internal purposes Resolver in the Agilent Field, shall terminate and expire
as of the Early Termination Date. To the extent any Agilent Technology is
incorporated into the design, development, manufacture or use of Resolver or
any Component thereof as of the Early Termination Date, Rosetta shall have,
and Agilent hereby grants to Rosetta, a worldwide, non-exclusive, irrevocable
license in, to and under Agilent Technology to design, develop, use, make,
have made, market, distribute, offer for sale, sell, reproduce, prepare
derivative works, display and perform publicly and support Resolver or any
Component thereof for the duration of the term of any valid patent within the
Agilent Patents covering Resolver or any Component thereof and Rosetta shall,
for the duration of such period, pay to Agilent a royalty equal to [***] on
Net Revenues associated with the Royalty Bearing Portion of Resolver taking
into account the Agilent Technology so incorporated; such royalty payments to
be made at such times and pursuant to the reports required to be delivered in
accordance with Section 7.7 hereof.

                  In the event Agilent shall terminate this Agreement
pursuant to Section 10.2, Agilent shall, as of the Early Termination Date,
have the right to purchase from Rosetta, and Rosetta shall, for so long as it
shall continue to offer for sale or sell Resolver, sell Resolver to Agilent
as [***] at the lowest of (i) [***] or (ii) [***].

                  In the event Rosetta shall not as of the Early Termination
Date or at any time thereafter continue to offer for sale or sell Resolver,
Agilent shall have, and Rosetta hereby grants to Agilent, a non-exclusive,
worldwide (outside of Korea), irrevocable license in, to and under the Rosetta
Technology to design, develop, use, make, have made, market, distribute, offer
for sale, sell, reproduce, prepare derivative works, display and perform
publicly and support

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -36-
<PAGE>

Resolver and any Component thereof for the later of (i) the duration of the
term of any valid patent within the Rosetta Patents covering Resolver or any
Component thereof or (ii) for so long (but in no event beyond the tenth
(10th) anniversary of the Early Termination Date) as Rosetta Know-How
incorporated therein remains material to the design, development, manufacture
or use thereof and Agilent shall, for the duration of such period, pay to
Rosetta commercially reasonable royalty on Net Revenues associated with the
Royalty Bearing Portion of Resolver or any other software product offered for
sale by Agilent incorporating such Rosetta Technology into the design,
development, manufacture or use thereof. Upon the request of Agilent at any
time after Rosetta shall no longer be offering for sale or selling Resolver,
Rosetta shall provide Agilent the source code and related documentation
therefor.

                  (c) ARRAYS. In the event either Rosetta or Agilent shall
terminate this Agreement pursuant to Section 10.2 hereof, Rosetta shall have,
and Agilent hereby grants, a fully paid, world-wide, non-exclusive, irrevocable,
royalty free license under the Agilent Technology to design, develop, use,
support and manufacture Arrays for internal use only (internal use includes,
without limitation, the right to use Arrays in providing commercial services to
Third Parties).

                  In the event Rosetta shall terminate this Agreement
pursuant to Section 10.2 hereof, as of the Early Termination Date, Rosetta
shall have right to purchase from Agilent, and Agilent shall, for so long as
it shall continue to offer for sale or sell Arrays, be obligated to sell to
Rosetta, Arrays at a [***] the price charged to Rosetta for Arrays pursuant
to Section 7.9 hereof, provided that if Agilent shall terminate this
Agreement pursuant to Section 10.2, Rosetta shall not have the right to any
special pricing of Arrays.

                  In the event after any termination pursuant to Section 10.2
Agilent shall continue to offer for sale or sell Arrays incorporating Inkjet
Technology or aspects of the Rosetta Technology that pertain to the
fabrication of Arrays in the development, manufacture or use thereof, Agilent
shall have, and Rosetta hereby grants to Agilent, a worldwide, non-exclusive,
irrevocable license in, to and under the Inkjet Technology or such aspects of
the Rosetta Technology that pertain to the fabrication of Arrays to
manufacture, market, offer for sale, sell and support Arrays (including in
connection with [***]) except in connection with the field of [***] for the
later of (i) the duration of the term of any valid patent within the licensed
Inkjet Technology or such aspects of the Rosetta Technology that pertain to
the fabrication of Arrays covering the design, manufacture or use of an Array
or any Component thereof or (ii) for so long (but in no event beyond the
tenth (10th) anniversary of the Early Termination Date) as Rosetta Know-How
incorporated therein remains material to the design, development, manufacture
or use of an Array or any Component thereof, and Agilent shall, for the
duration of such period, pay Rosetta a royalty equal to (A) [***] (if Rosetta
shall have terminated this Agreement pursuant to Section 10.2) or (B) [***]
(if Agilent shall have terminated this Agreement pursuant to Section 10.2),
times the royalty (calculated on a percentage basis), if any, required to be
paid to Rosetta in connection with Net Revenues of such Arrays as of the
Early Termination Date, or if there shall not as of the Early Termination
Date be in effect any such royalty payment obligation, a royalty equal to (A)
[***] (if Rosetta shall have terminated this Agreement pursuant to Section
10.2) or (B) [***] (if Agilent shall

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -37-
<PAGE>

have terminated this Agreement pursuant to Section 10.2) times the royalty
(calculated on a percentage basis) that would otherwise constitute a
commercially reasonable royalty taking into account the Rosetta Technology so
incorporated; such royalty payments to be made at such times and pursuant to the
reports required to be delivered in accordance with Section 7.7 hereof.

                  (d) PAMELA SYSTEM. In the event Rosetta shall terminate
this agreement pursuant to Section 10.2, all rights granted to Agilent by
Rosetta hereunder in respect of the Pamela System (other than the right to
use the Pamela System for internal purposes) shall terminate and expire as of
the Early Termination Date. To the extent any Rosetta Technology is
incorporated into the design, development, manufacture or use of the Pamela
System or any Component thereof as of the Early Termination Date, Agilent
shall have, and Rosetta hereby grants to Agilent, a worldwide (outside of
Korea), non-exclusive, irrevocable license in, to and under the Rosetta
Technology to manufacture, market, offer for sale, sell and support the
Pamela System or any Component thereof, for the later of (i) the duration of
the term of any valid patent within the Rosetta Patents covering the design,
manufacture or use of the Pamela System or any Component thereof or (ii) for
so long (but in no event beyond the tenth (10th) anniversary of the Early
Termination Date) as Rosetta Know-How incorporated therein remains material
to the design, development, manufacture or use thereof, and if on or prior to
such date Agilent shall have agreed or otherwise paid to Rosetta a royalty
with respect to Rosetta Technology incorporated into the design, development,
manufacturing or use of the Pamela System, Agilent shall, for the duration of
such period, pay to Rosetta a royalty equal to [***] times the royalty
(calculated on a percentage basis) paid to Rosetta in connection with Net
Revenues associated with the Royalty Bearing Portion of any Pamela System
taking into account the Rosetta Technology so incorporated (as evidenced by
the royalty rate in effect as of the Early Termination Date); such royalty
payments to be made at such times and pursuant to the reports required to be
delivered in accordance with Section 7.7 hereof.

                  In the event Agilent shall terminate this Agreement
pursuant to Section 10.2, all rights granted to Rosetta by Agilent hereunder
in respect of the Pamela System (other than the right to use the Pamela
System for internal purposes) shall terminate and expire as of the Early
Termination Date. To the extent any Rosetta Technology is incorporated into
the design, development, manufacture or use of the Pamela System or any
Component thereof as of the Early Termination Date, Agilent shall have, and
Rosetta hereby grants to Agilent, a worldwide, non-exclusive, irrevocable
license in, to and under Rosetta Technology to manufacture, market, offer for
sale, sell and support the Pamela System and any Component thereof, for the
later of (i) the duration of the term of any valid patent within the Rosetta
Patents covering the design, manufacture or use of the Pamela System or any
Component thereof or (ii) for so long (but in no event beyond the tenth
(10th) anniversary of the Early Termination Date) as Rosetta Know-How
incorporated therein remains material to the design, development, manufacture
or use thereof, and if on or prior to such date Agilent shall have agreed or
otherwise paid to Rosetta a royalty with respect to Rosetta Technology
incorporated into the design, development, manufacture or use of the Pamela
System, Agilent shall, for the duration of such period, pay Rosetta a royalty
equal to [***] of the royalty (calculated on a percentage basis) required to
be paid to Rosetta in connection with Net Revenues associated with the
Royalty Bearing Portion of any Pamela System taking into account the Rosetta
Technology so incorporated (as evidenced by the royalty

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -38-
<PAGE>

rate in effect as of the Early Termination Date); such royalty payments to be
made at such times and pursuant to the reports required to be delivered in
accordance with Section 7.7 hereof.

                  (e) OLIGO SET DESIGN SERVICES AND OTHER COLLABORATION
PRODUCTS. In the event this Agreement is terminated by either Party pursuant to
Section 10.2, the Parties shall agree on an allocation of rights subsequent to
the Early Termination Date in respect of Oligo Set Design Services and
Collaboration Products which became Collaboration Products during the Term
pursuant to Section 2.2 hereof. The Parties agree to allocate such rights in a
manner consistent with the terms governing the allocation of rights with respect
to the Collaboration Products expressly set forth herein, and to the extent
possible to preserve the relative competitive positions of the Parties with
respect to such Oligo Set Design Services and Collaboration Products which
became Collaboration Products during the Term pursuant to Section 2.2 hereof.

                  (f) NON-COLLABORATION PRODUCTS AND NEW PRODUCTS THAT BECOME
COLLABORATION PRODUCTS. The provisions of this Agreement and the arrangements of
the Parties for any royalties or other amounts owed one to the other on the sale
or other disposition of Non-Collaboration Products or New Products that become
Collaboration Products shall remain unchanged (unless otherwise agreed in
writing) in the event of any termination by any Party pursuant to Section 10.2.

11.      INDEMNIFICATION AND LIMITATION OF LIABILITY

         11.1 INDEMNIFICATION BY ROSETTA. Rosetta shall (i) indemnify and hold
harmless Agilent, its Affiliates, and all their officers, directors, employees
and agents, for any losses, claims, damages, judgments, assessments, costs and
other liabilities, including reasonable out-of-pocket costs and expenses as they
are incurred by Agilent in connection with any demands, law suits and other
legal actions by Third Parties against Agilent arising from any gross negligence
or willful misconduct by Rosetta, its Affiliates, agents or sublicensees,
provided, however, for purposes of this Section 11.1(i), neither gross
negligence nor willful misconduct shall be deemed to include conduct determined
to be infringement of patent, copyright, trademark, trade name, other
proprietary right, or an unauthorized use of a trade secret and (ii)
notwithstanding clause (i) of this Section 11.1 at Agilent's option, indemnify,
defend and hold harmless Agilent, its Affiliates and subsidiaries, and their
respective officers, directors, employees, agents and customers (but only to the
extent Agilent or any of its Affiliates or subsidiaries is contractually
obligated to indemnify such customers) for any claims, damages, judgments,
assessments, costs and other liabilities, including reasonable out-of-pocket
costs and expenses as they are incurred by Agilent in connection with any claim,
suit, or proceeding alleging that Resolver, including Resolver support and
maintenance services, or Oligo Set Design Services provided by Rosetta
(excluding any Component of or Collaboration Product Enhancement to Resolver or
such Oligo Set Design Services for which Agilent has Engineering
Responsibility), or any other Collaboration Product for which Rosetta has
Engineering Responsibility (unless otherwise agreed) or any documentation
relating to such products and services (all such products, services and
documents hereinafter referred to as "Rosetta Indemnification Products"),
constitutes an infringement of any Third Party's patent, copyright, trademark,
trade name, other proprietary right, or an unauthorized use of a trade secret.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -39-
<PAGE>

         11.2 INDEMNIFICATION BY AGILENT. Agilent shall (i) indemnify and hold
harmless Rosetta, its Affiliates, and all their officers, directors, employees
and agents, for any losses, claims, damages, judgments, assessments, costs and
other liabilities, including reasonable out-of-pocket costs and expenses as they
are incurred by Rosetta in connection with any demands, law suits and other
legal actions by Third Parties against Rosetta arising from any gross negligence
or willful misconduct by Agilent, its Affiliates, agents or sublicensees,
provided, however, for purposes of this Section 11.2(i), neither gross
negligence nor willful misconduct shall be deemed to include conduct determined
to be infringement of patent, copyright, trademark, trade name, other
proprietary right, or an unauthorized use of a trade secret and (ii)
notwithstanding clause (i) of this Section 11.1, at Rosetta's option, indemnify,
defend and hold harmless Rosetta, its Affiliates and subsidiaries, and their
respective officers, directors, employees, agents and customers (but only to the
extent Rosetta or any of its Affiliates or subsidiaries is contractually
obligated to indemnify such customers) for any claims, damages, judgments,
assessments, court costs and other liabilities, including reasonable
out-of-pocket costs and expenses as they are incurred by Rosetta in connection
with any claim, suit, or proceeding alleging that Arrays or the Pamela System or
any Component of either thereof (excluding any Component of or Collaboration
Product Enhancement to an Array or the Pamela System for which Rosetta has
Engineering Responsibility), or any other Collaboration Product for which
Agilent has Engineering Responsibility (unless otherwise agreed) or any
documentation relating to such products (all such products and documents
hereinafter referred to as "Agilent Indemnification Products"), constitutes an
infringement of any Third Party's patent, copyright, trademark, trade name,
other proprietary right, or an unauthorized use of a trade secret.

         11.3 INJUNCTIONS. In case any Rosetta Indemnification Product or
Agilent Indemnification Product, as the case may be, or any Component of any
thereof is held to constitute an infringement and its use is enjoined, Rosetta
or Agilent, as the case may be, shall at its own expense, at its option (i)
procure the right for the Indemnitee to continue to use the Rosetta
Indemnification Product or the Agilent Indemnification Product, as the case may
be, or (ii) if applicable, replace the same with a non-infringing product,
service or documentation of equivalent function and performance, or (iii) modify
such product, service or documentation such that it shall be noninfringing
without materially detracting from its function or performance. In the event
that, through the exercise of reasonable commercial efforts, the Indemnitor is
unable to accomplish any of the three (3) options, further performance under
this Section 11.3 is excused.

         11.4 CONDITIONS AND LIMITATIONS OF INDEMNIFICATION OBLIGATION.

                  (a) In order to maintain the right to be indemnified by the
other Party ("Indemnitor"), the Party claiming indemnification ("Indemnitee")
must:

                           (i) notify the Indemnitor promptly after learning of
any legal action undertaken by a Third Party and related to the subject matter
of this Article 11 (a "Third Party Claim");

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -40-
<PAGE>

                           (ii) allow the Indemnitor to manage and control (by
way of intervention or otherwise) the defense and settlement of any such Third
Party Claim against the Indemnitee;

                           (iii) cooperate with the Indemnitor in the defense or
the settlement negotiations of Third Party Claims as reasonable required by the
Indemnitor; and

                           (iv) abstain from making any statements or taking any
actions which damage the defense against a Third Party Claim (including, without
limitation, any statements against the interest of the Indemnitee or admissions
of causation or guilt).

                  (b) The Indemnitor shall not agree to any settlement that
adversely affects the Indemnitee's rights or interest without the Indemnitee's
prior written approval (which approval shall not be unreasonably withheld).

                  (c) The Indemnitor shall have no obligation to indemnify the
Indemnitee to the extent that a Third Party Claim results from the negligence or
willful misconduct of the Indemnitee.

         11.5 LIMITATION OF LIABILITY. SUBJECT TO THE INDEMNIFICATION OBLIGATION
SET FORTH HEREIN AND UNLESS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT,
NEITHER PARTY WILL BE LIABLE TO THE OTHER WITH RESPECT TO THE SUBJECT MATTER OF
THIS AGREEMENT FOR ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL, SPECIAL, OR PUNITIVE
DAMAGES, OR LOST PROFITS OR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS,
TECHNOLOGY OR SERVICES REGARDLESS OF WHETHER ANY SUCH CLAIM FOR DAMAGES, LOST
PROFITS OR OTHER COSTS IS BASED ON TORT, WARRANTY, CONTRACT OR ANY OTHER LEGAL
THEORY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

         11.6 RISK OF FAILURE; NO REPRESENTATIONS. The Parties recognize that
risk is inherent in development efforts such as those being undertaken in this
Agreement. Both Parties voluntarily assume this risk. Accordingly, a failure of
any Agilent Technology, Rosetta Technology or Collaboration Product developed
under this Agreement to perform as desired despite the reasonable efforts of the
responsible Party or Parties will not be deemed to be a breach of this
Agreement. NO PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
WITH RESPECT TO PATENTS OWNED OR LICENSED BY THEM, OR ANY KNOW-HOW OR
COLLABORATION PRODUCTION INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF
NONINFRINGEMENT, PATENTABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.

12.      DISPUTES BETWEEN THE PARTIES

         12.1 SCOPE AND PURPOSE OF THIS ARTICLE. The purpose of this Article 12
is to set forth the procedures pursuant to which the Parties intend in good
faith to resolve any and all disagreements and disputes arising under or related
to this Agreement or its making, or the

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -41-
<PAGE>

activities of the Parties in connection with their efforts hereunder
(collectively, "Disputes"), provided, however, neither Party will be bound by
this Article 12 in the event any Dispute arises under or relating to Section
10.2 or Section 10.4 of this Agreement. The Parties shall follow these
procedures fully and exhaustively before initiating any litigation to resolve
any Dispute. However, nothing herein shall prevent a Party from filing suit
seeking equitable relief (mandatory or prohibitive) to prevent what it perceives
as imminent, irreparable harm or to compel a Party to specifically perform in
accordance with this Article 12, particularly Section 12.4, provided that if
such relief is granted, the Parties will stipulate that any further proceedings
in such suit shall be stayed pending the completion of the procedures set forth
herein. These procedures do not apply to any claims by unrelated Parties. The
Parties stipulate that the running of any applicable statute of limitations
shall toll effective upon the first notice given under Section 12.2 until thirty
(30) days after the completion of the mediation process provided in Section
12.4.

         12.2 NOTICE OF DISPUTE. A Party ("Notifying Party") that perceives a
Dispute with the other Party subject to this Section 12 may notify the other
Party in writing of any Disputes that it wants resolved. The Notifying Party
shall include in the notice a detailed statement of the Disputes and a summary
of the evidence and arguments supporting the position asserted. The other Party
("Responsive Party") shall respond to the notice within ten (10) days after
receipt thereof and may include with its response a cross-notice of any Disputes
that the Responsive Party wants resolved. If a Responsive Party raises an
additional Dispute, the Notifying Party shall then respond to such cross-notice
within seven (7) days after receipt of the Responsive Party's cross-notice. All
notices, cross-notices and responses shall be in writing and sent by facsimile
with a confirming copy sent by first class mail.

         12.3 UNAIDED NEGOTIATIONS BETWEEN THE PARTIES. Initially the
Collaboration Managers shall meet at a mutually acceptable time and place within
fourteen (14) days after delivery of the final response, and thereafter as often
as they deem necessary, to exchange relevant information and attempt to resolve
the dispute. If the matter is not resolved by the Collaboration Managers within
thirty (30) days of receipt of the Notifying Party's first written notice, or if
such Collaboration Managers fail to meet within fourteen (14) days after
delivery of the final response, the Dispute shall be referred to the Executive
Sponsors. The Executive Sponsors shall likewise meet, with or without the
respective Collaboration Managers, at a mutually acceptable time and place
within ten (10) days after such referral, and thereafter as often as they
reasonably deem necessary, to exchange information and attempt to resolve the
Dispute. All meetings to be held under this Section 12.3 may be held in person,
or may be held by means of telephone or similar communications equipment.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -42-
<PAGE>

         12.4     NON-BINDING MEDIATION.

                  (a) COMMENCEMENT OF NON-BINDING MEDIATION. If the Parties
involved in the Dispute have not succeeded in negotiating a resolution of the
Dispute through unaided negotiations as contemplated in Section 12.3, within
thirty (30) days of the first meeting of the Executive Sponsors, or if the
Executive Sponsors do not meet within ten (10) days after such referral, the
Notifying Party may initiate the process for having a formal mediation conducted
by an impartial mediator. The Parties shall select a mediator, who shall have a
background in the industry or subject matter of the Dispute, acceptable to each
Party involved in the Dispute. If all Parties involved in the Dispute do not
agree on the selection of a mediator, any Party to the Dispute may apply to the
court for appointment of a mediator. The person selected or appointed shall be
required, as a condition of serving as the mediator, to sign an agreement
providing that (a) the mediator hold in confidence and not disclose to any other
person any information, or material (whether disclosed orally or in writing)
that a Party designates as confidential and (b) the mediator be disqualified as
a trial witness, consultant, or expert of a Party, except for the limited
purpose of providing any agreed settlement. Within five (5) days of the
selection or appointment of the mediator, each Party involved in the Dispute
shall submit to the mediator all dates within the following sixty (60) days when
it would be available for mediation. The mediator shall select the date for the
mediation. The mediation shall be conducted in Santa Clara County, California in
the event the Notifying Party is Rosetta, and in King County, Washington in the
event Agilent is the Notifying Party.

                  (b) CONDUCT OF MEDIATION. The mediation shall be conducted in
accordance with the then current Model Procedure for Mediation of Business
Disputes promulgated by the Center for Public Resources, except as otherwise
provided herein or as the Parties involved in the Dispute may otherwise agree in
writing. The Parties may engage in discovery in accordance with the procedures
that the Parties adopt, or in the absence of such agreement, in accordance with
the procedures set out in such Model Procedure or as allowed by the mediator. At
least seven (7) days prior to the date set for the mediation, each Party
involved in the Dispute shall deliver to the other Party and the mediator any
documents, exhibits, briefs, or other materials it intends to introduce or offer
during the course of the mediation. The mediator may not consider any written,
graphic or visual information not so provided. Each Party involved in the
Dispute shall appear when directed by the mediator and be fully prepared to
discuss in good faith a resolution of all Disputes. No Party involved in the
Dispute shall have any ex parte contact with the mediator, unless such contact
is initiated by the mediator.

                  (c) EFFECT OF DECISION OR SETTLEMENT. The decision of the
mediator shall be in all respects non-binding. However, the Parties involved in
the Dispute may at any time enter into an enforceable, written settlement
agreement.

                  (d) CONFIDENTIALITY. All discussions, offers, notices,
responses or other oral or written statements made in connection with the
procedures set out in this Section 12.4 shall be treated as settlement
negotiations within the meaning of Federal Rule of Evidence 408 or the
applicable State counterpart. Evidence of conduct or statements made in
connection with these procedures shall not be admissible in any other forum or
proceeding, except to prove the terms of

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -43-
<PAGE>

an agreed settlement. This Section 12.4(d) does not require the exclusion of any
evidence, otherwise admissible, because of its use or disclosure in connection
with these procedures.

         12.5 LITIGATION. If, after completing the above procedures set out in
Section 12.4, the Parties involved in the Dispute have not resolved fully all
Disputes, any Party involved in an unresolved Dispute may file suit in such
jurisdiction as it shall deem appropriate.

         12.6 GOVERNING LAW. This Agreement and all questions, claims, disputes,
remedies or procedural matters relating to Disputes under this Agreement shall
be interpreted in accordance with and governed exclusively by the laws of the
State of California, U.S.A., without regard to the principles of conflicts of
law.

13.      MISCELLANEOUS

         13.1 EFFECTS OF BANKRUPTCY. The Parties understand and agree that the
rights and licenses granted under or pursuant to this Agreement by one Party to
the other are, for all purposes of Section 365(n) of Title 11 of the United
States Code, licenses of rights to "intellectual property" as defined in Title
11, and that each Party, as licensee of such rights under this Agreement shall
retain and may fully exercise all of its rights and elections under Title 11.

         13.2 FORCE MAJEURE. Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, earthquake, explosion, flood, strike, lockout, embargo, act
of God, or any other similar or dissimilar cause beyond the control of the
defaulting Party, provided that the Party claiming force majeure has exerted all
reasonable efforts to avoid or remedy such force majeure.

         13.3 NO RECRUITING. Neither Party shall solicit or seek to employ
any person who is an employee of the other Party during the term of this
Agreement and for one (1) year thereafter. However, this clause does not
prevent either Party from engaging in recruiting activities directed to the
community at large and not targeted specifically at employees of the other,
even if such activities result in recruiting an employee of the other. This
shall not preclude either Party from receiving and accepting unsolicited
applications from such employees.

         13.4 ASSIGNMENT; CONFLICT.

                  (a) Except as expressly permitted by this Agreement, neither
Party may assign any of its rights or obligations under this Agreement to a
Third Party except in connection with a merger, acquisition or similar
reorganization or the sale of all or substantially all of its assets, or
otherwise with the prior written consent of the other Party. This Agreement
shall survive any such merger, acquisition or reorganization of either Party
with or into, or such sale of assets to, another Party and no consent for such
merger, acquisition, reorganization or sale shall be required hereunder;
provided, that in the event of such merger, acquisition, reorganization or sale,
no intellectual property rights of the acquiring corporation shall be included
in the

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -44-
<PAGE>

technology licensed hereunder. With regard to Agilent, this Section shall refer
to Agilent's Chemical Analysis Group and not the entire company.

                  (b) This Agreement shall be binding upon and inure to the
benefit of the successors and permitted assigns of the Parties. Any assignment
not in accordance with this Agreement shall be void. Not withstanding any
provisions in this Agreement to the contrary, upon the transfer of the
Hewlett-Packard Company assets and personnel dealing with the subject matter of
this Agreement to Agilent Technologies, Inc., on or about November 1, 1999, this
Agreement shall on such date be automatically transferred to, and shall be
binding upon, Agilent Technologies, Inc.

                  (c) If any term, condition or provision of the Business Plan,
Development Plan, Manufacturing Plan, Marketing Plan or Product Plan conflicts
with any term, condition or provision of this Agreement, this Agreement shall
control.

         13.5 SEVERABILITY. If any term, condition or provision of this
Agreement is held to be unenforceable for any reason, it shall, if possible, be
interpreted rather than voided, in order to achieve the intent of the Parties to
this Agreement to the extent possible. In any event, all other terms, conditions
and provisions of this Agreement shall be deemed valid and enforceable to the
full extent.

         13.6 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

         13.7 ENTIRE AGREEMENT; AMENDMENTS IN WRITING. This Agreement and the
Stock Purchase Agreement described in Section 7.1 together comprise the entire
understanding between the Parties with respect to their subject matter and
supersede any previous communications, representations, or agreements (including
the HR-1 Agreement, whether oral or written. All information heretofore
exchanged between the Parties pursuant to the Confidentiality Agreement
heretofore entered into between the Parties will henceforth be subject to the
applicable provisions of this Agreement. For purposes of construction, this
Agreement will be deemed to have been drafted by both Parties. No modification
of this Agreement will be binding on either Party unless in writing and signed
by an authorized representative of each Party.

         13.8 NOTICE. Any notice or other communication required or permitted to
be given to either Party hereto shall be in writing and shall be deemed to have
been properly given and to be effective on the date of delivery if delivered in
person, by facsimile or by nationally recognized express courier, or effective
fourteen (14) days after mailing by U.S. Postal Service, postage prepaid, as
Registered or Express Mail, postage paid, to the other Party at the following
address:

   Rosetta:       Rosetta Inpharmatics, Inc.
                  12040 - 115th Ave. NE
                  Kirkland, WA  98034
                  Attn.:  President

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -45-
<PAGE>

                  With copy to:
                  Venture Law Group
                  4750 Carillon Point
                  Kirkland, WA  98033
                  Attn.:  William Ericson

   Agilent:       Hewlett-Packard Company
                  3500 Deer Creek Road
                  Palo Alto, CA  94304
                  Attn.:  General Manager, Bioscience Products

                  with copy to:
                  Hewlett-Packard Company
                  Corporate Legal Dept.
                  3000 Hanover St.
                  Palo Alto, CA  94304
                  Attn.:  General Counsel

         Either Party may change its address for communications by a notice to
the other Party in accordance with this section.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -46-
<PAGE>

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first set forth above.

ROSETTA INPHARMATICS, INC.                  HEWLETT-PACKARD COMPANY

By:                                         By:
    ---------------------------------           --------------------------------

                                SIGNATURE PAGE TO
                     GENE EXPRESSION COLLABORATION AGREEMENT

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

                                                                   Exhibit 10.30

                                    EXHIBIT A

                         BSP US PATENTS AND APPLICATIONS

Patent No./              Title
Application No.

5,551,487                Micro-Dispenser for Preparing Assay Plates
5,585,639                Optical Scanning Apparatus
5,601,980                Manufacturing Method and Apparatus for Biological
                         Probe Arrays Using Vision-Assisted Micropipetting
5,675,443                Method and Apparatus for Imaging Through a Planar,
                         Transparent Substrate at an Oblique Angle
5,677,197                Biochemical Assay Plate and Method for Making the Same
5,683,875                Method for Detecting a Target Nucleic Acid Analyte
                         in a Sample
5,705,813                Integrated Planar Liquid Handling System for
                         MALDI-TOF MS
5,716,825                Integrated Nucleic Acid Analysis System for
                         MALDI-TOF MS
5,721,435                Methods and Apparatus for Measuring Optical
                         Properties of Biological and Chemical Substances
5,763,870                Method and System for Operating a Laser Device
                         Employing an Integral Power-Regulation Sensor
5,834,957                Implementing Asynchronous Sequential Circuits Using
                         Synchronous Design Techniques and Modules
5,837,475                Apparatus and Method for Scanning a Chemical Array
5,853,993                Signal Enhancement Method and Kit
5,900,949                CCD Imager for Confocal Scanning Microscopy
5,910,288                Method and Apparatus for Mixing a Thin Film of Fluid
5,910,410                Dual Tag Binding Assay
5,922,534                Dry Biochemical Assay Plate and Method for Making
                         the Same
5,945,679                Apparatus for Scanning a Chemical Array

[***]

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

<PAGE>

                                    EXHIBIT B

                             COLLABORATION PRODUCTS

The Collaboration Products include the following:

1.   Arrays (as defined in the Agreement)

2.   Resolver (as defined in the Agreement

3.   Oligo Set Design Services (as defined in the Agreement)

4.   Pamela System (as defined in the Agreement)

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -2-

<PAGE>

                                    EXHIBIT C

                                 INK JET PATENTS

US Patent Applications - licensed from the University of Washington

<TABLE>
<CAPTION>
Title                            Serial No.         Filed

<S>                              <C>                <C>
Solvent for Oligonucleotide      08/821,156         3/20/97
Synthesis and Methods of Use
(R97-001-17)
[***]                              [***]            [***]
</TABLE>

Foreign Patent Applications - licensed from the University of Washington

<TABLE>
<CAPTION>
File No.                         Country        Serial No.         Filed

<S>                              <C>            <C>                <C>

[***]                             [***]           [***]            [***]
[***]
</TABLE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -3-

<PAGE>

                                    EXHIBIT D

                            OLIGO SET DESIGN PATENTS

US Patent Applications - owned by Rosetta

<TABLE>
<CAPTION>
Title                            Serial No.         Filed

<S>                              <C>                <C>
[***]                              [***]            [***]
[***]                              [***]            [***]
[***]                              [***]            [***]
[***]                              [***]            [***]
[***]                              [***]            [***]
</TABLE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -4-

<PAGE>

                                    EXHIBIT E

                         FEATURES OF RESOLVER-TM- SOFTWARE

IMAGE VIEWER

View and interpret images representing primary data for a given profiling
technology.

PLOT VIEWER

A flexible plotting engine for experiments, profiles. and genes with powerful
analytical features to help decision making and the presentation of results.

TABLE VIEWER

View expression data for experiments, profiles, and genes in a customizable
spreadsheet format. Sort & export data for use in other applications. Rearrange,
show, or hide columns to tailor the display to the user's needs.

CORRELATION PLOT VIEWER

Using the Correlation Plot Viewer, pairs of genes, profiles, or experiments in
the user's gene expression database can be quickly compared.

SYNCHRONIZATION

Synchronization refers to the Resolver application's ability to share selected
data among many different tools. Use synchronization to quickly and effectively
visualize and analyze data identified in one tool using a second tool.

ROLE-BASED SECURITY SYSTEM

The role-based security system delivered with the Resolver application provides
row-level access control for all cell lines, tissues, hybridizations, profiles,
and experiments.

PERSISTENT USER PROFILES

Persistent user profiles allow all users to set preferences for the way they use
the Resolver application-table configuration, statistical cutoffs, highlighting,
etc., and have those same options in place the next time they use the Resolver,
even if the system is accessed using another client machine.

ANNOTATION MANAGERS FOR CELL LINES/TISSUES, NUCLEIC ACID PREPARATIONS (PREPS),
AND HYBRIDIZATIONS (HYBS)

The Resolver application includes spreadsheet-like interfaces and forms for
scientists to effectively manage cell lines and tissues, RNA samples,
hybridizations, and experiments tracked within the system.

QUALITY STATISTICS

The Resolver application includes easy-to-understand quality statistics,
including P-values on every gene expression measurement. Using these statistics,
even the subtlest transcriptional responses can be characterized by repeating
expression profiles and combining them into statistically averaged experiments
within the Resolver application.

ROSETTA ARRAY SEARCH TOOL ("ROAST")

Use ROAST (Rosetta Array Search Tool), to compare one gene, experiment, or
expression profile against others in the database. This tool is analogous to the
BLAST sequence analysis tool.

USER-DEFINED BIOSETS

Use the BioSets features in the Resolver application to group and store
collections of genes or experiments of interest and perform set manipulation on
these groups. Add annotation and comments to BioSets and, if desired, share them
collaboratively with other Resolver users.

COMMENT SYSTEM

An easy-to-use comment system allows users to add or view comments about genes,
experiments, expression profiles, or BioSets and even respond to comments made
by other users. View comments in hierarchical newsgroup-like format or in table
format.

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -5-

<PAGE>

INSTALINKR~ PRODUCTIVITY LINK SYSTEM

Use InstaLink to quickly access bioinformatics resources within the Resolver
application, on the World Wide Web, or on the user's Intranet that aid in the
analysis of a particular datapoint within the application. Medline, Entrez, and
other databases can be searched with two clicks using this feature. The user can
add personalized productivity links to Internet and Intranet sites.

CLUSTER ANALYSIS ENGINE

Analyze gene expression data, and identify co-regulated gene sets and classes of
similar compounds using a high-performance, flexible cluster analysis engine.

CLUSTER TREE VIEWER

Visualize and analyze data from the Cluster Analysis Engine in a compact,
convenient hyperbolic display. Search for genes or experiments of interest, and
zoom, magnify, move, or rotate trees to identify clusters of interest.

SERVER ADMINISTRATION TOOLS

Use these configuration interfaces and control panels to administer and
customize the Resolver application.

-------------
 * Resolver is a trademark of Rosetta Inpharmatics. Inc.

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -6-

<PAGE>

                                    EXHIBIT F

                                 ROSETTA PATENTS

US Patent Applications - owned by Rosetta

<TABLE>
<CAPTION>
File No.                         Serial No.         Filed

<S>                              <C>                <C>
[***]                              [***]            [***]
[***]                              [***]            [***]
</TABLE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -7-

<PAGE>

                                    EXHIBIT G

                     POTENTIAL RESOLVER TAP SALES CUSTOMERS

CUSTOMER NAME

[***]

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -8-

<PAGE>

                                    EXHIBIT H

                   PERMITTED ARRAY MANUFACTURING SUB-LICENSES

      COMPANY NAME

      None established or identified as of the Effective Date

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -9-

<PAGE>

                                    EXHIBIT I

                   PERMITTED PAMELA MANUFACTURING SUB-LICENSES

      COMPANY NAME

Amersham Pharmacia Biotech
New England Nuclear (NEN) Qiogen

                          PERMITTED PAMELA DISTRIBUTORS

See Agilent Technologies' Chemical Analysis Group authorized distributors in
Exhibit J

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -10-

<PAGE>

                                    EXHIBIT J

                         PERMITTED RESOLVER DISTRIBUTORS

Agilent Technologies' Chemical Analysis Group Authorized Distributors

Company Name                                      Company Country

ABC Instrumentacion Analitica                     Mexico
Acme Instruments                                  United States
Aioi Denkl                                        Japan
Alfaquimia, S.L.                                  Spain
Al-Khaldiya. Co.                                  Kuwait
Alpha Omega                                       United States
Alsi Ltd.                                         Ukraine
Analitek, S.A.                                    Mexico
ANALITICA s.n.c.                                  Italy
Analogic Solutions, Limited                       Trinidad and Tobago
Analytical Technology & Research Corp.            Philippines
Andaluza de Instrumentacion                       Spain
Andaluza de Instrumentacion, S.L.                 Spain
Anorss                                            Spain
APG Service                                       Russia
Atas Benelux b.v.                                 Netherlands
Bafang Technology Ltd                             China
Beijing Ghaosheng Tech Dev. Co.                   China
Belhard Ltd.                                      Belarus
BIOS ANALYTIQUE                                   France
Boom b.v.                                         Netherlands
C Labor                                           Hungary
C.P.S. Analitica s.r.l.                           Italy
CARETEK                                           Labanon
Carl Stuart Ltd.                                  Ireland
Carl Stuart Ltd.                                  United Kingdom
Casa Cientifica Blanco y Cia, S.A. De C.V.        Colombia
Centro de Capacitacion Analitica                  Argentina
Chemetrix Ltd.                                    South Afria
Chempex Sdn Bhd                                   Malaysia
Chromacol Limited                                 United Kingdom
Chromatography Inc.                               United States
Chromatography  Sciences  Company (CSC)           Canada
ChromPikas                                        Lithuania
Chrom Tech AB                                     Sweden
Crawford Scientific Limited                       United Kingdom
DSP-Chromatography d.o.o.                         Yugoslavia
Ducray Lenior Ltd                                 Mauritius
Duratec GmbH                                      Germany
E.Merck Nederland b.v.                            Netherlands
Eldan Electronic Instruments Ltd.                 Israel
EMITAC                                            United Arab Emirates
Emsica S.R.L.                                     Paraguay
Esslab Limited                                    United Kingdom
Executive Trading Ltd.                            Thailand
Fielquimec Cia, Ltda.                             Ecuador
Fisher Scientific                                 United States
GC DIAGNOSTICS LTDA.                              Brazil
Gholkar's                                         United States
Gino Co. Ltd.                                     China
GMP S.A.                                          Switzerland
Government Scientific Source                      United States
Hellamco                                          Greece
Hellma Sulamericana I e E. Ltda.                  Brazil
Hermes Plus d.d.                                  Slovenia
Hermes Plus d.o.o.                                Croatia
Hermes Plus Hungary                               Hungary
Hermes Plus Skopje                                Macedonia
Hermes Plus Slovakia s.r.o.                       Slovak Republic
HESS                                              United States
HiChrom Limited                                   United Kingdom
Hui-Pu Tian-Di International Co. Ltd.             China
IBS s.s.                                          Albania
IMTAC                                             Oman
Infochroma AG                                     Switzerland
Inpac International Corp.                         Taiwan
Instrelec                                         Argentina
Instrumenta, S.A.                                 Peru
INTERCHIM                                         France
Interface Engineering Co. Ltd.                    South Korea
Interlab GmbH                                     Austria
Inula Ogussa Ges.m.b.H.                           Austria
Ipesa de Guatemala, S.A.                          Guatemala
IT Technologies Pte Ltd.                          Singapore
JL & T                                            Argentina
Jurgens & Co. GmbH                                Germany
Kbymos                                            Colombia
L.G.R. Lab Supplie                                United States
Labcrom Instrumentos Cientificos                  Brazil
LANTANA                                           Brazil
Lara Spiral                                       France
LWL Dev Ltd                                       China
M.I.S. Co Ltd                                     Nigeria
MacMod                                            United States
Mario Raul Delfino                                Argentina
Medtec Products Limited                           New Zealand
Merck-Belgolabo n.v./s.a.                         Beigium
Metlab Supplies Limited                           United Kingdom
Milian S.A.                                       Switzerland
Modern Electronic Establishment                   Saudi Arabia
Nishikawa Keisoku                                 Japan
Omnilab S.R.L.                                    Argentina
Orascom                                           Egypt
Pablo Ferrando, S.A. y C.                         Uruguay
PORTOLAB INSTRUMENTACAO                           Brazil
CIENTIFICA E DIAGNOSTICA
Precision Electronique                            Tunisia
Precision Tech Services                           Sri Lanka
Prodima, S.A.                                     Panama
Proquinorte, S.A.                                 Spain
Provisoriamente                                   Peru
PR Berca Indonesia                                Indonesia
Qatar Datamation systems                          Qatar
Quimica Norte                                     Argentina
Reedy Scientific                                  United States
S&T Plus s.r.o.                                   Czech Republic
S.C. High-Res s.r.l.                              Romania
S.M.S. Scientific & Medical Supplies              Jordan
Scaneast                                          Kazakhstan
Schmidt Medical                                   Hong Kong
Sem Laboratuar                                    Turkey
Serlab, S.A.                                      Spain
Serisa de C.V.                                    El Salvador
Sincetech Instruments                             Taiwan
SINTESE ARTIGOS PARA                              Brazil
LABORATORIOS
Sobovat SA                                        Morocco
Soquimica                                         Portugal
SPECTRA                                           Brazil
SRA Instruments                                   France
StepBio s.r.l.                                    Italy
Suministros Tecnicos S.R.L.                       Argentina
Systematic Insturments Co Ltd                     Taiwan
Team Ltd                                          Bulgaria
Tecnolab S.n.c.                                   Italy
Tegent Technology Ltd                             China
Tegent Technology Ltd                             Hong Kong
Texel                                             Argentina
Tramat Co Ltd                                     Vietnam
VWR Canlab                                        Canada
VWR Scientific Products                           United States
Wagner & Munz Ges.m.b.H.                          Austria
Wagner & Munz GmbH                                Germany
Weisser Analitica                                 Chile
WiCom GmbH                                        Germany
Wipro Biomed                                      India
Young-In Scientific Co Ltd                        South Korea

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -11-

<PAGE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -12-

<PAGE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -13-

<PAGE>

                                    EXHIBIT K

                           PREFERRED ESCROW AGREEMENT

                                    SEE TAB 3

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -14-

<PAGE>

                                    EXHIBIT L

                     ROYALTY-BEARING COLLABORATION PRODUCTS

<TABLE>
<CAPTION>
                             % Royalty Rate Paid
Product                       Rosetta by Agilent               Stacking
-------                      -------------------               --------
<S>                          <C>                               <C>
[***]                              [***]                         [***]
[***]                              [***]                         [***]
</TABLE>

REVENUE-SHARING COLLABORATION PRODUCTS

<TABLE>
<CAPTION>
                             Revenue Share % Due            Revenue Share %
Revenue Source                    Agilent                     Due Rosetta
--------------               -------------------            ---------------
<S>                          <C>                            <C>
[***]                              [***]                         [***]
[***]                              [***]                         [***]
[***]                              [***]                         [***]
[***]                              [***]                         [***]
</TABLE>

COLLABORATION PRODUCTS
SUBJECT TO NEITHER ROYALTY NOR REVENUE SHARING

<TABLE>
<CAPTION>
Product                     Royalty Revenue Share          Royalty Stacking
-------                     ---------------------          ----------------
<S>                         <C>                            <C>
[***]                              [***]                         [***]
[***]                              [***]                         [***]
</TABLE>

----------
* Material has been omitted pursuant to a request for confidential treatment,
  and such material has been filed separately with the SEC.

                                      -15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]